se-II=mol.carcinogen.   (25)

1. IF (2004): 18.122
   Bernards R. A functional approach to questions about life, death, and phosphorylation. Cancer Cell 2005; 7 (6): 503-504.
   PM:15950899 

2. IF (2004): 0.876
   Brummelkamp TR, Berns K, Hijmans EM, Mullenders J, Fabius A, Heimerikx M, Velds A, Kerkhoven RM, Madiredjo M, Bernards R, Beijersbergen RL. Functional identification of cancer-relevant genes through large-scale RNA interference screens in mammalian cells. Cold Spring Harb Symp Quant Biol 2004; 69 439-445.
   PM:16117679 

3. IF (2004): 6.355
   Celie PH, Klaassen RV, Rossum-Fikkert SE, van Elk R, van Nierop P, Smit AB, Sixma TK. Crystal structure of acetylcholine-binding protein from Bulinus truncatus reveals the conserved structural scaffold and sites of variation in nicotinic acetylcholine receptors. J Biol Chem 2005; 280 (28): 26457-26466.
   PM:15899893 

4. IF (2004): 12.000
   Celie PH, Kasheverov IE, Mordvintsev DY, Hogg RC, van Nierop P, van Elk R, Rossum-Fikkert SE, Zhmak MN, Bertrand D, Tsetlin V, Sixma TK, Smit AB. Crystal structure of nicotinic acetylcholine receptor homolog AChBP in complex with an alpha-conotoxin PnIA variant. Nat Struct Mol Biol 2005; 12 (7): 582-588.
   PM:15951818 

5. IF (2004): 16.385
   Creyghton MP, Roël G, Eichhorn PJA, Hijmans EM, Maurere I, Destr‚e O, Bernards R. PR72, a novel regulator of Wnt signaling required for naked cuticle function. Genes Dev 2005; 19 (3): 376-386.

    

6. IF (2004): 7.690
   Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, Stoughton R, Friend S. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005; 65 (10): 4059-4066.
   PM:15899795 

7. IF (2004): 1.392
   Dirac AM, Nijman SM, Brummelkamp TR, Bernards R. Functional annotation of deubiquitinating enzymes using RNA interference. Methods Enzymol 2005; 398 554-567.
   PM:16275358 

8. IF (2004): 28.389
   Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005; 122 (6): 835-847.
   PM:16179254 

9. IF (2004): 9.782
   Glas AM, Kersten MJ, Delahaye LJ, Witteveen AT, Kibbelaar RE, Velds A, Wessels LFA, Joosten P, Kerkhoven RM, Bernards R, Van Krieken JHJM, Kluin PM, Van't Veer LJ, De Jong D. Gene expression profiling in follicular l ymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105 301-307.
   PM:15345589 

10. IF (2004): 28.389
    Kolfschoten IG, van Leeuwen B, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM, Agami R. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 2005; 121 (6): 849-858.
    PM:15960973

11. IF (2004): 20.649
    Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, Clevers H, Medema RH. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005; 7 (2): 126-136.
    PM:15654331 

12. IF (2004): 5.185
    Lebbink JH, Sixma TK. Variations on the ABC. Structure 2005; 13 (4): 498-500.
    PM:15837186 

13. IF (2004): 6.355
    Litjens SH, Wilhelmsen K, de Pereda JM, Perrakis A, Sonnenberg A. Modeling and experimental validation of the binary complex of the plectin actin-binding domain and the first pair of fibronectin type III (FNIII) domains of the beta4 integrin. J Biol Chem 2005; 280 (23): 22270-22277.
    PM:15817481 

14. IF (2004): 5.623
    Middelburg R, de Haas RR, Dekker H, Kerkhoven RM, Pohlmann PR, Fuentes-Alburo A, Mohar A, Pinedo HM, Lankelma J. Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. Clin Cancer Res 2005; 11 (5): 1863-1869.
    PM:15756011 

15. IF (2004): 1.693
    Newman J, Egan D, Walter TS, Meged R, Berry I, Ben Jelloul M, Sussman JL, Stuart DI, Perrakis A. Towards rationalization of crystallization screening for small- to medium-sized academic laboratories: the PACT/JCSG+ strategy. Acta Crystallogr D Biol Crystallogr 2005; 61 (Pt 10): 1426-1431.
    PM:16204897 

16. IF (2004): 16.811
    Nicke B, Bastien J, Khanna SJ, Warne PH, Cowling V, Cook SJ, Peters G, Delpuech O, Schulze A, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Ganesan TS, Downward J, Hancock DC. Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells 10. Mol Cell 2005; 20 (5): 673-685.
    PM:16337592 

17. IF (2004): 16.811
    Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D'Andrea AD, Bernards R. The Deubiquitinating Enzyme USP1 Regulates the Fanconi Anemia Pathway. Mol Cell 2005; 17 (3): 331-339.
    PM:15694335 

18. IF (2004): 28.389
    Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R. A genomic and functional inventory of deubiquitinating enzymes 18. Cell 2005; 123 (5): 773-786.
    PM:16325574 

19. Nijman,S.M.B. Ubiquitin, signaling, and cancer [dissertation]. Utrecht University; 2005;

     

20. IF (2004): 12.000
    Pichler A, Knipscheer P, Oberhofer E, van Dijk WJ, Korner R, Olsen JV, Jentsch S, Melchior F, Sixma TK. SUMO modification of the ubiquitin-conjugating enzyme E2-25K. Nat Struct Mol Biol 2005; 12 (3): 264-269.
    PM:15723079 

21. IF (2004): 5.375
    Quante M, Heeg S, von Werder A, Goessel G, Fulda C, Doebele M, Nakagawa H, Beijersbergen R, Blum HE, Opitz OG. Differential transcriptional regulation of human telomerase in a cellular model representing important genetic alterations in esophageal squamous carcinogenesis. Carcinogenesis 2005; 26 (11): 1879-1889.
    PM:15958520 

22. IF (2004): 20.649
    Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 2005; 7 1074-1082.
    PM:16244670 

23. Van Amerongen,R. The mouse trap: resolving the role of Frat in Wnt-signal transduction [dissertation]. University of Amsterdam; 2005;

     

24. IF (2004): 6.355
    Van Meeteren LA, Ruurs P, Christodoulou E, Goding JW, Takakusa H, Kikuchi K, Perrakis A, Nagano T, Moolenaar WH. Inhibition of autotaxin by lysophosphatidic acid and sphingosine-1-phosphate. J Biol Chem 2005; 280 21155-21161.
    PM:15769751 

25. IF (2004): 20.649
    Wanzel M, Kleine-Kohlbrecher D, Herold S, Hock A, Berns K, Park J, Hemmings B, Eilers M. Akt and 14-3-3eta regulate Miz1 to control cell-cycle arrest after DNA damage. Nat Cell Biol 2005; 7 (1): 30-41.
    PM:15580267

se-III=cell.biochem.    (28)

1. IF (2004): 9.782
   Bacchiocchi R, Baldanzi G, Carbonari D, Capomagi C, Colombo E, Van Blitterswijk WJ, Graziani A, Fazioli F. Activation of alpha-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase. Blood 2005; 106 (6): 2175-2182.
   PM:15928040 

2. IF (2004): 13.054
   Berkers CR, Ovaa H. Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol Sci 2005; 26 (5): 252-257.
   PM:15860372 

3. IF (2004): geen
   Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2005; 2 (5): 357-362.
   PM:15846363 

4. IF (2004): 3.118
   Bertolino P, Deckers M, Lebrin F, Ten Dijke P. TGF-á signal transduction in angiogenesis and vascular disorders. Chest 2005; 128 585S-590S.
   PM:16373850 

5. IF (2004): 3.474
   Borodovsky A, Ovaa H, Meester WJ, Venanzi ES, Bogyo MS, Hekking BG, Ploegh HL, Kessler BM, Overkleeft HS. Small-molecule inhibitors and probes for ubiquitin- and ubiquitin-like-specific proteases. Chembiochem 2005; 6 (2): 287-291.
   PM:15651044 

6. IF (2004): 18.122
   Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8 (5): 407-419.
   PM:16286248 

7. IF (2004): 5.076
   Durgam GG, Virag T, Walker MD, Tsukahara R, Yasuda S, Liliom K, Van Meeteren LA, Moolenaar WH, Wilke N, Siess W, Tigyi G, Miller DD. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin 404. J Med Chem 2005; 48 (15): 4919-4930.
   PM:16033271 

8. IF (2004): 4.824
   Eyüpoglu IY, Hahnen E, Buslei R, Siebzehnrubl FA, Savaskan NE, Luders M, Trankle C, Wick W, Weller M, Fahlbusch R, Blumcke I. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 2005; 93 (4): 992-999.
   PM:15857402 

9. IF (2004): 1.392
   Galardy PJ, Ploegh HL, Ovaa H. Mechanism-based proteomics tools based on ubiquitin and ubiquitin-like proteins: crystallography, activity profiling, and protease identification. Methods Enzymol 2005; 399 120-131.

    

10. IF (2004): 13.054
    Halstead JR, Jalink K, Divecha N. An emerging role for PtdIns(4,5)P(2)-mediated signalling in human disease. Trends Pharmacol Sci 2005; 26 654-660.
    PM:16253350 

11. IF (2004): 4.575
    Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res 2005; 65 (3): 599-608.
    PM:15664386 

12. IF (2004): 6.486
    Lin AH, Luo J, Mondshein LH, Ten Dijke P, Vivien D, Contag CH, Wyss-Coray T. Global analysis of Smad2/3-dependent TGF-beta signaling in living mice reveals prominent tissue-specific responses to injury. J Immunol 2005; 175 (1): 547-554.
    PM:15972691 

13. IF (2004): 16.811
    Meulmeester E, Maurice MM, Boutell C, Teunisse AF, Ovaa H, Abraham TE, Dirks RW, Jochemsen AG. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell 2005; 18 (5): 565-576.
    PM:15916963 

14. IF (2004): 6.355
    Misaghi S, Galardy PJ, Meester WJ, Ovaa H, Ploegh HL, Gaudet R. Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. J Biol Chem 2005; 280 (2): 1512-1520.
    PM:15531586 

15. IF (2004): 3.843
    Mulder J, Ariaens A, van Horck FP, Moolenaar WH. Inhibition of RhoA-mediated SRF activation by p116(Rip). FEBS Lett 2005; 579 (27): 6121-6127.
    PM:16243315 

16. Mulder,J. p116Rip: a new player in RhoA signalling [dissertation]. Leiden University; 2005;

     

17. IF (2004): 1.961
    Nedic O, Baricevic I, Golubovic S, Jones DR. New considerations for IGFBP-3 determination in human serum. Clin Chim Acta 2005; 361 (1-2): 211-213.
    PM:16084962 

18. IF (2004): 1.392
    Ovaa H, Galardy PJ, Ploegh HL. Mechanism-based proteomics tools based on ubiquitin and ubiquitin-like proteins: synthesis of active site-directed probes. Methods Enzymol 2005; 399 468-478.

     

19. Ovaa H, Overkleeft HS, Kessler BM, et al. Mayer RJ, Ciechanover AJ, Rechsteiner M, editors.Protein degradation, Vol. 2: The Ubiquitin-Proteasome System. Weinheim: Wiley-VCH, 2005;Dissecting intramolecular proteolysis using small molecule inhibitors and molecular probes.

     

20. IF (2004): 5.005
    Sayama K, Komatsuzawa H, Yamasaki K, Shirakata Y, Hanakawa Y, Ouhara K, Tokumaru S, Dai X, Tohyama M, Ten Dijke P, Sugai M, Ichijo H, Hashimoto K. New mechanisms of skin innate immunity: ASK1-mediated keratinocyte differentiation regulates the expression of beta-defensins, LL37, and TLR2. Eur J Immunol 2005; 35 (6): 1886-1895.
    PM:15864780 

21. IF (2004): 5.725
    Tseng HC, Ovaa H, Wei NJ, Ploegh H, Tsai LH. Phosphoproteomic analysis with a solid-phase capture-release-tag approach. Chem Biol 2005; 12 (7): 769-777.
    PM:16039524 

22. IF (2004): 6.355
    Van Baal J, De Widt J, Divecha N, Van Blitterswijk WJ. Translocation of diacylglycerolkinase zeta from cytosol to plasma membrane in response to activation of G-protein-coupled receptors and protein kinase C. J Biol Chem 2005; 280 9870-9878.

     

23. IF (2004): geen
    van Leeuwen F, van Steensel B. Histone modifications: from genome-wide maps to functional insights. Genome Biol 2005; 6 (6): 113
    PM:15960810  

24. IF (2004): 6.355
    Van Meeteren LA, Ruurs P, Christodoulou E, Goding JW, Takakusa H, Kikuchi K, Perrakis A, Nagano T, Moolenaar WH. Inhibition of autotaxin by lysophosphatidic acid and sphingosine-1-phosphate. J Biol Chem 2005; 280 21155-21161.
    PM:15769751 

25. IF (2004): 3.250
    van Rossum AG, Schuuring-Scholtes E, Buuren-van Seggelen V, Kluin PM, Schuuring E. Comparative genome analysis of cortactin and HS1: the significance of the F-actin binding repeat domain. BMC Genomics 2005; 6 (1): 15
    PM:15710041 

26. IF (2004): 4.335
    Veldman RJ, Koning GA, van Hell A, Zerp S, Vink SR, Storm G, Verheij M, Van Blitterswijk WJ. Co-formulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin. J Pharmacol Exp Ther 2005; 315 704-710.
    PM:16040815 

27. IF (2004): 1.854
    Vink SR, Schellens JHM, Van Blitterswijk WJ, Verheij M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs 2005; 23 (4): 279-286.
    PM:16012787 

28. IF (2004): 1.341
    Zingler N, Weichenrieder O, Schumann GG. APE-type non-LTR retrotransposons: determinants involved in target site recognition. Cytogenet Genome Res 2005; 110 (1-4): 250-268.
    PM:16093679

se-IV=immunol.   (18)

1. IF (2004): 6.486
   Arens R, Baars PA, Jak M, Tesselaar K, Van Der Valk M, van Oers MH, van Lier RA. Cutting edge: CD95 maintains effector T cell homeostasis in chronic immune activation. J Immunol 2005; 174 (10): 5915-5920.
   PM:15879081 

2. IF (2004): 5.005
   Baars PA, Sierro S, Arens R, Tesselaar K, Hooibrink B, Klenerman P, van Lier RA. Properties of murine CD8(+)CD27(-) T cells. Eur J Immunol 2005; 35 (11): 3131-3141.
   PM:16220536 

3. IF (2004): 11.565
   Bakker AH, Schumacher TNM. MHC multimer technology: current status and future prospects. Curr Opin Immunol 2005; 17 (4): 428-433.
   PM:15967654 

4. IF (2004): 31.223
   Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC, Schumacher TNM, Haanen JBAG. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005; 11 (8): 899-904.
   PM:15965482 

5. IF (2004): 11.565
   Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005; 17 (3): 275-281.
   PM:15886117 

6. IF (2004): 2.664
   Bronke C, Palmer NM, Westerlaken GHA, Toebes M, van Schijndel GMW, Purwaha V, Van Meijgaarden KE, Schumacher TNM, Van Baarle D, Tesselaar K, Geluk A. Direct Ex Vivo detection of HLA-DR3-restricted cytomegalovirus- and mycobacterium tuberculosis-specific CD4+ T cells. Hum Immunol 2005; 66 (9): 950-961.

    

7. IF (2004): geen
   Coccoris M, de Witte MA, Schumacher TNM. Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther 2005; 5 (6): 583-593.
   http://www.ingentaconnect.com/search/article?author=coccoris&year_from=2005&year_to=2005&database=1&pageSize=20&index=1 

8. IF (2004): 6.486
   Hendriks J, Xiao Y, Rossen JW, van der Sluijs KF, Sugamura K, Ishii N, Borst J. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J Immunol 2005; 175 (3): 1665-1676.
   PM:16034107 

9. IF (2004): 7.260
   Jansen JG, Tsaalbi-Shtylik A, Langerak P, Calleja F, Meijers CM, Jacobs H, De Wind N. The BRCT domain of mammalian Rev1 is involved in regulating DNA translesion synthesis. Nucleic Acids Res 2005; 33 (1): 356-365.
   PM:15653636 

10. IF (2004): geen
    Kessels HW, Wolkers MC, Schumacher TNM. Gene transfer of MHC-restricted receptors. Methods Mol Med 2005; 109 201-214.
    PM:15585923 

11. IF (2004): 7.260
    Langerak P, Nygren AOH, Schouten JP, Jacobs H. Rapid and quantitative detection of homologous and non-homologous recombination events using three oligonucleotide MLPA. Nucleic Acids Res 2005; 33 e188
    PM:16340005   

     

12. IF (2004): 9.835
    Luiten RM, Kueter EW, Mooi W, Gallee MPW, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC. Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients. J Clin Oncol 2005; 23 8978-8991.
    PM:16260696 

13. IF (2004): 5.005
    Matter M, Mumprecht S, Pinschewer DD, Pavelic V, Yagita H, Krautwald S, Borst J, Ochsenbein AF. Virus-induced polyclonal B cell activation improves protective CTL memory via retained CD27 expression on memory CTL. Eur J Immunol 2005; 35 (11): 3229-3239.
    PM:16231287 

14. IF (2004): 27.586
    Nolte MA, Arens R, van Os R, van Oosterwijk M, Hooibrink B, van Lier RA, van Oers MH. Immune activation modulates hematopoiesis through interactions between CD27 and CD70. Nat Immunol 2005; 6 (4): 412-418.
    PM:15723067 

15. IF (2004): 5.398
    Ressing ME, Van Leeuwen D, Verreck FAW, Keating S, Gomez R, Franken K, Ottenhof THM, Spriggs M, Schumacher TNM, Hutt-Fletcher LM, Rowe M, Wiertz EJHJ. Epstein-Barr virus gp42 is posttranslationally modified to produce soluble s-gp42 that mediates HLA class II immune evasion. J Virol 2005; 79 841-852.
    PM:15613312 

16. IF (2004): 27.586
    Scheeren FA, Naspetti M, Diehl S, Schotte R, Nagasawa M, Wijnands E, Gimeno R, Vyth-Dreese FA, Blom B, Spits H. STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat Immunol 2005; 6 (3): 303-313.
    PM:15711548 

17. IF (2004): 4.812
    Schepers K, Arens R, Schumacher TNM. Dissection of cytotoxic and helper T cell responses. Cell Mol Life Sci 2005; 62 2695-2710.
    PM:16231088 

18. IF (2004): 2.651
    Verra N, De Jong D, Bex A, Batchelor D, Dellemijn T, Sein J, Nooijen W, Meinhardt W, Horenblas S, de Gast G, Vyth-Dreese F. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol 2005; 48 (3): 527-533.
    PM:16115526

se-V=mol.biol. (31)

1. IF (2004): 7.822
   Balciunaite E, Spektor A, Lents NH, Cam H, Te Riele H, Scime A, Rudnicki MA, Young R, Dynlacht BD. Pocket protein complexes are recruited to distinct targets in quiescent and proliferating cells. Mol Cell Biol 2005; 25 (18): 8166-8178.
   PM:16135806 

2. IF (2004): 1.744
   Borst P. Ethidium DNA agarose gel electrophoresis: How it started. IUBMB Life 2005; 57 (11): 745-747.
   PM:16511967 

    

3. Borst P. van Maanen H, editors.Kwakzalverij: 125 jaar medische folklore. Amsterdam: Boom, 2005;Moerman revisited. p. 124-31.

    

4. IF (2004): 7.690
   Breedveld P, Pluim D, Cipriani G, Wielinga P, Van Tellingen O, Schinkel AH, Schellens JHM. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005; 65 (7): 2577-2582.
   PM:15805252 

5. IF (2004): 16.811
   DiPaolo C, Kieft R, Cross M, Sabatini R. Regulation of trypanosome DNA glycosylation by a SWI2/SNF2-like protein. Mol Cell 2005; 17 (3): 441-451.
   PM:15694344 

6. IF (2004): 6.318
   Essafi A, Fernandez de Mattos S, Hassen YA, Soeiro I, Mufti GJ, Thomas NS, Medema RH, Lam EW. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 2005; 24 (14): 2317-2329.
   PM:15688014 

7. IF (2004): 18.122
   Foijer F, Wolthuis RM, Doodeman V, Medema RH, Te Riele H. Mitogen requirement for cell cycle progression in the absence of pocket protein activity. Cancer Cell 2005; 8 (6): 455-466.
   PM:16338659 

8. IF (2004): 7.260
   Genest PA, ter Riet B, Dumas C, Papadopoulou B, Van Luenen HG, Borst P. Formation of linear inverted repeat amplicons following targeting of an essential gene in Leishmania. Nucleic Acids Res 2005; 33 (5): 1699-1709.
   PM:15781496 

9. IF (2004): geen
   Jager A, Linn SC. Behandeling van gemetastaseerd mammacarcinoom na voorbehandeling met anthracyclines en taxanen. Ned Tijdschr Oncol 2005; 2 232-239.

    

10. Jonkers J, Berns A. Knowles MA, Selby PJ, editors.Introduction to the cellular and molecular biology of cancer, 4th ed. Oxford: Oxford University Press, 2005;Animal models of cancer. p. 317-36.

     

11. IF (2004): 6.318
    Kuiperij HB, van der Horst A, Raaijmakers J, Weijzen S, Medema RH, Bos JL, Burgering BM, Zwartkruis FJ. Activation of FoxO transcription factors contributes to the antiproliferative effect of cAMP. Oncogene 2005; 24 (12): 2087-2095.
    PM:15688004 

12. IF (2004): 20.649
    Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, Clevers H, Medema RH. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005; 7 (2): 126-136.
    PM:15654331 

13. IF (2004): geen
    Linn SC, Helgason HH, Oosterkamp HM. De MATADOR-studie: multicenter fase-III-onderzoek naar chemotherapie op maat bij het mammacarcinoom. Ned Tijdschr Oncol 2005; 2 193-198.

     

14. IF (2004): 10.416
    Manautou JE, de Waart DR, Kunne C, Zelcer N, Goedken M, Borst P, Oude Elferink R. Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 2005; 42 (5): 1091-1098.
    PM:16250050 

15. IF (2004): 5.242
    Norris MD, Smith J, Tanabe K, Tobin P, Flemming C, Scheffer GL, Wielinga P, Cohn SL, London WB, Marshall GM, Allen JD, Haber M. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther 2005; 4 (4): 547-553.
    PM:15827327 

16. IF (2004): 7.517
    Pellis-van Berkel W, Verheijen MHG, Cuppen E, Asahina M, de Rooij J, Jansen G, Plasterk RHA, Bos JL, Zwartkruis FJT. Requirement of the Caenorhabditis elegans RapGEF pxf-1 and rap-1 for epithelial integrity. Mol Biol Cell 2005; 16 (1): 106-116.
    PM:15525675 

17. IF (2004): 5.623
    Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res 2005; 11 (12): 4487-4494.
    PM:15958634 

18. IF (2004): 7.567
    Schmidt M, Budirahardja Y, Klompmaker R, Medema RH. Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Rep 2005; 6 (9): 866-872.
    PM:16113653 

19. IF (2004): 4.540
    Tavassoli M, Guelen L, Luxon BA, Gaken J. Apoptin: Specific killer of tumor cells? Apoptosis 2005; 10 (4): 717-724.
    PM:16133863 

20. IF (2004): 2.803
    Toaldo CB, Kieft R, Dirks-Mulder A, Sabatini R, Van Luenen HGAM, Borst P. A minor fraction of base J in kinetoplastid nuclear DNA is bound by the J-binding protein 1. Mol Biochem Parasitol 2005; 143 (1): 111-115.
    PM:15935489 

21. IF (2004): 16.385
    Van Amerongen R, Nawijn M, Franca-Koh J, Zevenhoven J, Van der Gulden H, Jonkers J, Berns A. Frat is dispensable for canonical Wnt signaling in mammals. Genes Dev 2005; 19 (4): 425-430.
    PM:15681612 

22. IF (2004): 7.822
    Van de Weerdt BC, van Vugt MA, Lindon C, Kauw JJ, Rozendaal MJ, Klompmaker R, Wolthuis RM, Medema RH. Uncoupling anaphase-promoting complex/cyclosome activity from spindle assembly checkpoint control by deregulating polo-like kinase 1. Mol Cell Biol 2005; 25 (5): 2031-2044.
    PM:15713655 

23. IF (2004): 7.260
    van den Ijssel P, Tijssen M, Chin SF, Eijk P, Carvalho B, Hopmans E, Holstege H, Bangarusamy DK, Jonkers J, Meijer GA, Caldas C, Ylstra B. Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res 2005; 33 (22): e192
    PM:16361265 

24. IF (2004): 5.959
    Van Luenen HG, Kieft R, Mussmann R, Engstler M, ter Riet B, Borst P. Trypanosomes change their transferrin receptor expression to allow effective uptake of host transferrin. Mol Microbiol 2005; 58 (1): 151-165.
    PM:16164555 

25. IF (2004): 6.318
    van Vugt MA, Medema RH. Getting in and out of mitosis with Polo-like kinase-1. Oncogene 2005; 24 (17): 2844-2859.
    PM:15838519 

26. Van Vugt,M.A.T. Cell cycle regulation by Polo-like kinase-1 [dissertation]. University Utrecht; 2005;

     

27. Van Vugt MATM, Medema RH. Brooks G, Humphrey TC, editors.Cell cycle protocols: methods and techniques. Totowa: Humana Press, 2005;Polo-like kinase-1: activity measurements and RNAi-mediated knockdown. p. 296-369.

     

28. IF (2004): 6.355
    Verlinden L, Eelen G, Beullens I, Van Camp M, Van Hummelen P, Engelen K, Van Hellemont R, Marchal K, De Moor B, Foijer F, Te Riele H, Beullens M, Bollen M, Mathieu C, Bouillon R, Verstuyf A. Characterization of the condensin component Cnap1 and protein kinase Melk as novel E2F target genes down-regulated by 1,25-dihydroxyvitamin D3. J Biol Chem 2005; 280 (45): 37319-37330.
    PM:16144839 

29. IF (2004): 7.690
    Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, van der Born K, de Haas M, van der Heijden I, Kaspers G, Wijnholds J, Jansen G, Peters G, Borst P. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates 389. Cancer Res 2005; 65 (10): 4425-4430.
    PM:15899835 

30. IF (2004): 7.690
    Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res 2005; 65 (18): 8166-8173.
    PM:16166291 

31. IF (2004): 10.452
    Zelcer N, van de Wetering K, Hillebrand M, Sarton E, Kuil A, Wielinga PR, Tephly T, Dahan A, Beijnen JH, Borst P. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci U S A 2005; 102 (20): 7274-7279.
    PM:15886284

se-VI=tumor biol.   (30)

1. IF (2004): 7.186
   Angenieux C, Fraisier V, Maitre B, Racine V, van der Wel N, Fricker D, Proamer F, Sachse M, Cazenave JP, Peters P, Goud B, Hanau D, Sibarita JB, Salamero J, de la Salle H. The cellular pathway of CD1e in immature and maturing dendritic cells. Traffic 2005; 6 (4): 286-302.
   PM:15752135 

2. IF (2004): 5.005
   Boes M, van der Wel N, Peperzak V, Kim YM, Peters PJ, Ploegh H. In vivo control of endosomal architecture by class II-associated invariant chain and cathepsin S. Eur J Immunol 2005; 35 (9): 2552-2562.
   PM:16094690 

3. IF (2004): 9.782
   de Almeida SF, Carvalho IF, Cardoso CS, Cordeiro JV, Azevedo JE, Neefjes J, de Sousa M. HFE cross-talks with the MHC class I antigen presentation pathway. Blood 2005; 106 (3): 971-977.
   PM:15840699 

4. IF (2004): 7.822
   Duursma A, Agami R. p53-Dependent regulation of Cdc6 protein stability controls cellular proliferation. Mol Cell Biol 2005; 25 (16): 6937-6947.
   PM:16055707 

5. IF (2004): geen
   Duursma AM, Agami R. CDK-dependent stabilization of Cdc6: linking growth and stress signals to activation of DNA replication 50. Cell Cycle 2005; 4 (12): 1725-1728.
   PM:16258286 

6. IF (2004): 3.843
   Einav Y, Agami R, Canaani D. shRNA-mediated RNA interference as a tool for genetic synthetic lethality screening in mouse embryo fibroblasts 184. FEBS Lett 2005; 579 (1): 199-202.
   PM:15620713 

7. IF (2004): 6.910
   Fernandez-Borja M, Janssen L, Verwoerd D, Hordijk P, Neefjes J. RhoB regulates endosome transport by promoting actin assembly on endosomal membranes through Dia1. J Cell Sci 2005; 118 (Pt 12): 2661-2670.
   PM:15944396 

8. IF (2004): 4.009
   Greber UF, Fornerod M. Nuclear trafficking in viral infections. Curr Top Microbiol Immunol 2005; 285 109-138.
   PM:15609502 

9. IF (2004): 8.182
   Griekspoor A, Zwart W, Neefjes J. Presenting antigen presentation in living cells using biophysical techniques. Curr Opin Microbiol 2005; 8 (3): 338-343.
   PM:15939359 

10. IF (2004): 1.392
    Groothuis TAM, Reits EAJ. Monitoring the distribution and dynamics of proteasomes in living cells. Methods Enzymol 2005; 399 549-563.
    PM:16338381

     

11. IF (2004): 14.588
    Groothuis TAM, Neefjes J. The many roads to cross-presentation. J Exp Med 2005; 202 (10): 1313-1318.
    PM:16287713 

12. IF (2004): 7.878
    Groothuis TAM, Griekspoor AC, Neijssen JJ, Herberts CA, Neefjes JJ. MHC class I alleles and their exploration of the antigen-processing machinery. Immunol Rev 2005; 207 60-76.
    PM:16181327

     

13. IF (2004): 11.565
    Harding CV, Neefjes J. Antigen processing and recognition. Curr Opin Immunol 2005; 17 (1): 55-57.
    PM:15653311 

14. IF (2004): 11.602
    Hendriksen J, Fagotto F, van der Velde H, van Schie M, Noordermeer J, Fornerod M. RanBP3 enhances nuclear export of active (beta)-catenin independently of CRM1. J Cell Biol 2005; 171 (5): 785-797.
    PM:16314428 

15. IF (2004): 7.822
    Hernandez-Munoz I, Taghavi P, Kuijl C, Neefjes J, Van Lohuizen M. Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1. Mol Cell Biol 2005; 25 (24): 11047-11058.
    PM:16314526 

16. Jordens,I. Transport of lysosome-related organelles 5 [dissertation]. University Leiden; 2005;

     

17. IF (2004): 7.186
    Jordens I, Marsman M, Kuijl C, Neefjes J. Rab proteins, connecting transport and vesicle fusion. Traffic 2005; 6 (12): 1070-1077.
    PM:16262719 

18. IF (2004): 28.389
    Kolfschoten IG, van Leeuwen B, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM, Agami R. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 2005; 121 (6): 849-858.
    PM:15960973 

19. IF (2004): 10.452
    Koppers-Lalic D, Reits EAJ, Ressing ME, Lipinska AD, Abele R, Koch J, Rezende MM, Admiraal P, Van Leeuwen D, Bienkowska-Szewczyk K, Mettenleiter TC, Rijsewijk FAM, Tampe R, Neefjes J, Wiertz EJHJ. Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. Proc Natl Acad Sci U S A 2005; 102 (14): 5144-5149.
    PM:15793001 

20. IF (2004): 2.664
    Kuipers HF, Biesta PJ, Groothuis TAM, Neefjes JJ, Mommaas AM, van den Elsen PJ. Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum Immunol 2005; 66 (6): 653-665.
    PM:15993711 

21. IF (2004): 6.200
    Marsman M, Jordens I, Griekspoor A, Neefjes J. Chaperoning Antigen Presentation by MHC Class II Molecules and their Role in Oncogenesis. Adv Cancer Res 2005; 93 129-158.
    PM:15797446 

22. Marsman,M.A. Control of lysosomal and phago-lysosomal fusion and degradation [dissertation]. University Leiden; 2005;

     

23. IF (2004): 32.182
    Neijssen J, Herberts C, Drijfhout JW, Reits E, Janssen L, Neefjes J. Cross-presentation by intercellular peptide transfer through gap junctions. Nature 2005; 434 (7029): 83-88.
    PM:15744304 

24. IF (2004): 16.385
    Schwartz M, Zlotorynski E, Goldberg M, Ozeri E, Rahat A, le Sage C, Chen BP, Chen DJ, Agami R, Kerem B. Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability. Genes Dev 2005; 19 (22): 2715-2726.
    PM:16291645 

25. IF (2004): 8.182
    Swanson JA, Peters PJ. Techniques: Subcellular imaging technologies - microscopic visual thinking. Curr Opin Microbiol 2005; 8 (3): 313-315.

     

26. IF (2004): 28.389
    Touret N, Paroutis P, Terebiznik M, Harrison RE, Trombetta S, Pypaert M, Chow A, Jiang A, Shaw J, Yip C, Moore HP, van der Wel N, Houben D, Peters PJ, de Chastellier C, Mellman I, Grinstein S. Quantitative and dynamic assessment of the contribution of the ER to phagosome formation. Cell 2005; 123 (1): 157-170.
    PM:16213220 

27. IF (2004): 6.486
    Towne CF, York IA, Neijssen J, Karow ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Neefjes JJ, Rock KL. Leucine aminopeptidase is not essential for trimming peptides in the cytosol or generating epitopes for MHC class I antigen presentation. J Immunol 2005; 175 (10): 6605-6614.
    PM:16272315 

28. IF (2004): 8.182
    van der Wel NN, Fluitsma DM, Dascher CC, Brenner MB, Peters PJ. Subcellular localization of mycobacteria in tissues and detection of lipid antigens in organelles using cryo-techniques for light and electron microscopy. Curr Opin Microbiol 2005; 8 (3): 323-330.
    PM:15939357

29. IF (2004): 7.517
    Yan Q, Sun W, Kujala P, Lotfi Y, Vida TA, Bean AJ. CART: an Hrs/actinin-4/BERP/myosin V protein complex required for efficient receptor recycling. Mol Biol Cell 2005; 16 (5): 2470-2482.
    PM:15772161 

30. IF (2004): 15.448
    Zwart W, Griekspoor A, Kuijl C, Marsman M, Van Rheenen J, Janssen H, Calafat J, van Ham M, Janssen L, van Lith M, Jalink K, Neefjes J. Spatial Separation of HLA-DM/HLA-DR Interactions within MIIC and Phagosome-Induced Immune Escape. Immunity 2005; 22 (2): 221-233.
    PM:15723810

se-VII=mol.genet.     (31)

1. IF (2004): 28.389
   Berns A. Stem cells for lung cancer? Cell 2005; 121 (6): 811-813.
   PM:15960966 

2. IF (2004): 32.182
   Berns A. Cancer: two in one. Nature 2005; 436 (7052): 787-789.
   PM:16094355 

3. Berns A. Wiepkens PR, Schroten E, Van der Eb AJ, editors.Transgene dieren. 2005;Genetisch-gemodificeerde muizen: wat hebben we eraan? p. 23-40.

    

4. IF (2004): 21.713
   Boyle P, Ariyaratne M, Bartelink H, Baselga J, Berns A, Brawley OW, Burns H, Davidov M, Dinshaw KA, Dresler C, et al. Curbing tobacco's toll starts with the professionals: World No Tobacco Day. Lancet 2005; 365 (9476): 1990-1992.
   PM:15950704 

5. IF (2004): 16.385
   Bruggeman SW, Valk-Lingbeek ME, van der Stoop PP, Jacobs JJ, Kieboom K, Tanger E, Hulsman D, Leung C, Arsenijevic Y, Marino S, Van Lohuizen M. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 2005; 19 (12): 1438-1443.
   PM:15964995 

6. IF (2004): 10.382
   de Wit E, Greil F, van Steensel B. Genome-wide HP1 binding in Drosophila: developmental plasticity and genomic targeting signals. Genome Res 2005; 15 (9): 1265-1273.
   PM:16109969 

7. IF (2004): 7.690
   Geiger TR, Peeper DS. The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective. Cancer Res 2005; 65 (16): 7033-7036.
   PM:16103047 

8. IF (2004): 14.204
   Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F, Sevestre H, Krimpenfort P, Corsini A, Rochette J, Glineur C, Fruchart JC, Torpier G, Staels B. PPARalpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16. J Clin Invest 2005; 115 (11): 3228-3238.
   PM:16239970 

9. IF (2004): 4.278
   Hassink G, Kikkert M, van Voorden S, Lee SJ, Spaapen R, van Laar T, Coleman CS, Bartee E, Fruh K, Chau V, Wiertz E. TEB4 is a C4HC3 RING finger-containing ubiquitin ligase of the endoplasmic reticulum. Biochem J 2005; 388 (Pt 2): 647-655.
   PM:15673284 

10. IF (2004): 10.452
    Hernandez-Munoz I, Lund AH, Van der Stoop P, Boutsma E, Muijrers I, Verhoeven E, Nusinow DA, Panning B, Marahrens Y, Van Lohuizen M. Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc Natl Acad Sci U S A 2005; 102 (21): 7635-7640.
    PM:15897469 

11. IF (2004): 7.822
    Hernandez-Munoz I, Taghavi P, Kuijl C, Neefjes J, Van Lohuizen M. Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1. Mol Cell Biol 2005; 25 (24): 11047-11058.
    PM:16314526

12. IF (2004): 15.448
    Iwama A, Oguro H, Negishi M, Kato Y, Morita Y, Tsukui H, Ema H, Kamijo T, Katoh-Fukui Y, Koseki H, Van Lohuizen M, Nakauchi H. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 2004; 21 (6): 843-851.
    PM:15589172 

13. IF (2004): geen
    Jacobs JJ, de Lange T. p16INK4a as a second effector of the telomere damage pathway. Cell Cycle 2005; 4 (10): 1364-1368.
    PM:16177573 

14. Jonkers J, Berns A. Knowles MA, Selby PJ, editors.Introduction to the cellular and molecular biology of cancer, 4th ed. Oxford: Oxford University Press, 2005;Animal models of cancer. p. 317-36.

     

15. IF (2004): 7.517
    Klieger Y, Yizhar O, Zenvirth D, Shtepel-Milman N, Snoek M, Simchen G. Involvement of Sir2/4 in silencing of DNA breakage and recombination on mouse YACs during yeast meiosis. Mol Biol Cell 2005; 16 (3): 1449-1455.
    PM:15647382 

16. IF (2004): 1.464
    Linnoila RI, Naizhen X, Meuwissen R, Berns A, Demayo FJ. Mouse Lung Neuroendocrine Carcinomas: Distinct Morphologies, Same Transcription Factors. Exp Lung Res 2005; 31 (1): 37-55.
    PM:15765918 

17. IF (2004): 2.346
    Loden M, van Steensel B. Whole-genome views of chromatin structure. Chromosome Res 2005; 13 (3): 289-298.
    PM:15868422 

18. IF (2004): 9.835
    Luiten RM, Kueter EW, Mooi W, Gallee MPW, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC. Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients. J Clin Oncol 2005; 23 8978-8991.
    PM:16260696 

19. IF (2004): 7.690
    Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, Cleutjens KB, de Krijger R, Krimpenfort P, Berns A, van der Kwast TH, Trapman J. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 2005; 65 (13): 5730-5739.
    PM:15994948 

20. IF (2004): 16.385
    Meuwissen R, Berns A. Mouse models for human lung cancer. Genes Dev 2005; 19 (6): 643-664.
    PM:15769940 

21. IF (2004): 32.182
    Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436 (7051): 720-724.
    PM:16079850

22. IF (2004): 0.876
    Muyrers-Chen I, Hern ndez-Mu¤oz I, Lund AH, Valk-Lingbeek ME, Van der Stoop P, Boutsma E, Tolhuis B, Bruggeman SWM, Taghavi P, Verhoeven E, Hulsman D, Noback S, Tanger E, Theunissen H, Van Lohuizen M. Emerging roles of Polycomb silencing in X-inactivation and stem cell maintenance. Cold Spring Harb Symp Quant Biol 2004; 69 319-326.
    PM:16117664 

     

23. IF (2004): 20.649
    Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 2005; 7 1074-1082.
    PM:16244670 

24. Rowland,B.D. Cellular mechanisms of protection against oncogenic transformation [dissertation]. University Utrecht; 2005;

     

25. IF (2004): 6.318
    Uren AG, Kool J, Berns A, Van Lohuizen M. Retroviral insertional mutagenesis: past, present and future. Oncogene 2005; 24 (52): 7656-7672.
    PM:16299527 

26. Valk-Lingbeek,M. Role of the Ink4a/Arf tumor suppressors in cerebellar development, stem cells and cancer 2 [dissertation]. 2005;

     

27. IF (2004): 16.385
    Van Amerongen R, Nawijn M, Franca-Koh J, Zevenhoven J, Van der Gulden H, Jonkers J, Berns A. Frat is dispensable for canonical Wnt signaling in mammals. Genes Dev 2005; 19 (4): 425-430.
    PM:15681612

28. IF (2004): geen
    Van Amerongen R, Berns A. Re-Evaluating the Role of Frat in Wnt-Signal Transduction. Cell Cycle 2005; 4 (8): 1065-1072.
    PM:16082208 

29. IF (2004): geen
    van Leeuwen F, van Steensel B. Histone modifications: from genome-wide maps to functional insights. Genome Biol 2005; 6 (6): 113
    PM:15960810 

30. IF (2004): 24.695
    van Steensel B. Mapping of genetic and epigenetic regulatory networks using microarrays. Nat Genet 2005; 37 Suppl S18-S24
    PM:15920525 

31. IF (2004): 7.907
    Zencak D, Lingbeek M, Kostic C, Tekaya M, Tanger E, Hornfeld D, Jaquet M, Munier FL, Schorderet DF, Van Lohuizen M, Arsenijevic Y. Bmi1 loss produces an increase in astroglial cells and a decrease in neural stem cell population and proliferation. J Neurosci 2005; 25 (24): 5774-5783.
    PM:15958744

se-VIII=exp.ther.     (37)

1. IF (2004): 5.080
   Adachi Y, Suzuki H, Schinkel AH, Sugiyama Y. Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Mol Pharmacol 2005; 67 (3): 923-928.
   PM:15598971

2. IF (2004): 2.750
   Appels NMGM, Van Maanen MJ, Rosing H, Schellens JHM, Beijnen JH. Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19 (15): 2187-2192.
   PM:15996016 

3. IF (2004): 1.854
   Beumer JH, Hillebrand MJX, Pluim D, Rosing H, Foley K, Yule SM, Schellens JHM, Beijnen JH. Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients. Invest New Drugs 2005; 23 (4): 317-330.
   PM:16012791 

4. IF (2004): 7.690
   Breedveld P, Pluim D, Cipriani G, Wielinga P, Van Tellingen O, Schinkel AH, Schellens JHM. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005; 65 (7): 2577-2582.
   PM:15805252 

5. Breedveld,P. The role of BCRP ( ABCG2) in the preclinical pharmacology of anticancer drugs {De rol van BCRP (ABCG2) in de preklinische farmacologie van antikankermiddelen [dissertation]. Utrecht University; 2005;

    

6. IF (2004): 10.452
   Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, Van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, Van de Vijver MJ. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005; 102 (10): 3738-3743.
   PM:15701700 

7. IF (2004): 7.690
   Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, Stoughton R, Friend S. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005; 65 (10): 4059-4066.
   PM:15899795 

8. Faneyte,I.F. Markers for effectiveness of chemotherapy and drug resistance in breast cancer [dissertation]. University of Amsterdam; 2005;

    

9. IF (2004): 9.835
   Hannemann J, Oosterkamp HM, Bosch CAJ, Velds A, Wessels LFA, Loo C, Rutgers EJ, Rodenhuis S, Van de Vijver MJ. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005; 23 (15): 3331-3342.
   PM:15908647 

10. IF (2004): 4.416
    Huisman MT, Chhatta AA, Van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 2005; 116 824-829.
    PM:15849751 

11. IF (2004): 2.220
    Janssen HL, Balm AJM, Haustermans KM, Begg AC. Hypoxia in head and neck tumors: how much, how important? Head Neck 2005; 27 622-638.
    PM:15952198 

12. IF (2004): 4.297
    Janssen HL, Ljungkvist AS, Rijken PF, Sprong D, Bussink J, van der Kogel AJ, Haustermans KM, Begg AC. Thymidine analogues to assess microperfusion in human tumors. Int J Radiat Oncol Biol Phys 2005; 62 (4): 1169-1175.
    PM:15990022 

13. IF (2004): 31.223
    Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, Schinkel AH. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 2005; 11 (2): 127-129.
    PM:15685169 

14. IF (2004): 5.500
    Jonker JW, Freeman J, Bolscher E, Musters S, Alvi AJ, Titley I, Schinkel AH, Dale TC. Contribution of the ABC Transporters Bcrp1 and Mdr1a/1b to the Side Population Phenotype in Mammary Gland and Bone Marrow of Mice. Stem Cells 2005; 23 (8): 1059-1065.
    PM:16002779 

15. IF (2004): 2.940
    Kondo C, Onuki R, Kusuhara H, Suzuki H, Suzuki M, Okudaira N, Kojima M, Ishiwata K, Jonker JW, Sugiyama Y. Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2). Pharm Res 2005; 22 (4): 613-618.
    PM:15846469 

16. IF (2004): 4.335
    Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, Sugiyama Y. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther 2005; 312 (1): 44-52.
    PM:15448171 

17. IF (2004): 4.297
    Ljungkvist AS, Bussink J, Kaanders JH, Rijken PF, Begg AC, Raleigh JA, van der Kogel AJ. Hypoxic cell turnover in different solid tumor lines. Int J Radiat Oncol Biol Phys 2005; 62 (4): 1157-1168.
    PM:15913908

18. IF (2004): 3.836
    Merino G, Jonker JW, Wagenaar E, Pulido MM, Molina AJ, Alvarez AI, Schinkel AH. Transport of anthelmintic benzimidazole drugs by Breast Cancer Resistance Protein (BCRP/ABCG2). Drug Metab Dispos 2005; 33 614-618.
    PM:15703302 

19. IF (2004): 5.080
    Merino G, van Herwaarden AE, Wagenaar E, Jonker JW, Schinkel AH. Gender-dependent expression and activity of the ABC transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in liver. Mol Pharmacol 2005; 67 1765-1771.
    PM:15722455 

20. IF (2004): 5.080
    Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH. The Breast Cancer Resistance Protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 2005; 67 1758-1764.
    PM:15709111 

21. IF (2004): 2.216
    Mohrmann K, van Eijndhoven MA, Schinkel AH, Schellens JHM. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemother Pharmacol 2005; 56 (4): 344-350.
    PM:15875186 

22. IF (2004): 3.034
    Neijenhuis S, Begg AC, Vens C. Radiosensitization by a dominant negative to DNA polymerase beta is DNA polymerase beta-independent and XRCC1-dependent. Radiother Oncol 2005; 76 (2): 123-128.
    PM:16024118  

23. IF (2004): 4.335
    Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, Schinkel AH. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 2005; 312 (1): 144-152.
    PM:15365089 

24. IF (2004): 14.588
    Schneider E, Machavoine F, Pleau JM, Bertron AF, Thurmond RL, Ohtsu H, Watanabe T, Schinkel AH, Dy M. Organic cation transporter 3 modulates murine basophil functions by controlling intracellular histamine levels. J Exp Med 2005; 202 (3): 387-393.
    PM:16061728 

25. IF (2004): 5.080
    Sesink ALA, Arts ICW, de Boer VCJ, Breedveld P, Schellens JHM, Hollman PC, Russel FGM. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol Pharmacol 2005; 67 (6): 1999-2006.
    PM:15749994 

26. IF (2004): 2.054
    Triesscheijn M, Ruevekamp M, Aalders M, Baas P, Stewart FA. Outcome of mTHPC Mediated Photodynamic Therapy is Primarily Determined by the Vascular Response. Photochem Photobiol 2005; 81 (5): 1161-1167.
    PM:15934792 

27. IF (2004): 32.182
    Van Beers E, Klerkx A, Thiele A. Retreat to make progress: Dutch postdocs retreat to discuss career development [letter]. Nature 2005; 438 126
    PM:16287222

     

28. IF (2004): 7.690
    Van Beers EH, Van Welsem T, Wessels LFA, Oldenburg RA, Devilee P, Cornelisse CJ, Verhoef S, Hogervorst FBL, Van't Veer LJ, Nederlof PM. CGH profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 2005; 65 822-827.
    PM:15705879

     

29. IF (2004): 3.836
    van Herwaarden AE, Smit JW, Sparidans RW, Wagenaar E, van der Kruijssen CMM, Schellens JHM, Beijnen JH, Schinkel AH. Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. Drug Metab Dispos 2005; 33 (7): 892-895.
    PM:15845749 

30. IF (2004): 1.854
    Vink SR, Schellens JHM, Van Blitterswijk WJ, Verheij M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs 2005; 23 (4): 279-286.
    PM:16012787 

31. IF (2004): 4.500
    Voskuil DW, Vrieling A, Van't Veer LJ, Kampman E, Rookus MA. The insulin-like growth factor (IGF) system in cancer prevention: potential of dietary intervention strategies. Cancer Epidemiol Biomarkers Prev 2005; 13 195-203.
    PM:16041870 

32. IF (2004): 3.742
    Weigelt B, Wessels LFA, Bosma AJ, Glas AM, Nuyten DS, He YD, Dai H, Peterse JL, Van't Veer LJ. No common denominator for breast cancer lymph node metastasis. Br J Cancer 2005; 93 (8): 924-932.
    PM:16189523 

33. IF (2004): 36.557
    Weigelt B, Peterse JL, Van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5 (8): 591-602.
    PM:16056258 

34. IF (2004): 7.690
    Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, Van't Veer LJ. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005; 65 (20): 9155-9158.
    PM:16230372 

35. Weigelt,B. Molecular markers of breast cancer metastasis [dissertation]. University of Amsterdam; 2005;

     

36. IF (2004): 4.297
    West CM, McKay MJ, Holscher T, Baumann M, Stratford IJ, Bristow RG, Iwakawa M, Imai T, Zingde SM, Anscher MS, Bourhis J, Begg AC, Haustermans K, Bentzen SM, Hendry JH. Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. Int J Radiat Oncol Biol Phys 2005; 62 (5): 1264-1273.
    PM:16029781

37. IF (2004): 13.868
    West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, Rubin BP, Montgomery K, Zhu S, Patel R, Hernandez-Boussard T, Goldblum JR, Brown PO, van de Vijver M, van de Rijn M. Determination of stromal signatures in breast carcinoma. PLoS Biol 2005; 3 (6): e187
    PM:15869330

se-IX=radiother.     (57)

1. IF (2004): 4.297
   Aleman BMP, Girinsky T, Van Der Maazen RWM, Strijk S, Meijnders P, Bortolus R, Olofsen-van Acht MJ, Lybeert MLM, Lievens Y, Eghbali H, Noordijk EM, Tomsic R, Meerwaldt JH, Poortmans PMP, Smit WGJM, Pinna A, Henry-Amar M, Raemaekers JMM. Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884). Int J Radiat Oncol Biol Phys 2005; 63 (4): 1184-1190.
   PM:15936157 

2. IF (2004): geen
   Balm AJM, Schornagel JH, Rasch CRN. De rol van gelijktijdige chemotherapie en radiotherapie bij de behandeling van lokaal uitgebreide tumoren van larynx, farynx en mondholte. Ned Tijdschr Geneeskd 2005; 149 61-64.

    

3. IF (2004): 3.034
   Belderbos J, Heemsbergen W, Hoogeman M, Pengel K, Rossi M, Lebesque J. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. Radiother Oncol 2005; 75 (2): 157-164.
   PM:15890421 

4. IF (2004): 3.034
   Bohsung J, Gillis S, Arrans R, Bakai A, De Wagter C, Knoos T, Mijnheer BJ, Paiusco M, Perrin BA, Welleweerd H, Williams P. IMRT treatment planning:- a comparative inter-system and inter-centre planning exercise of the ESTRO QUASIMODO group. Radiother Oncol 2005; 76 (3): 354-361.
   PM:16154218 

5. IF (2004): 4.297
   Borst GR, De Jaeger K, Belderbos JSA, Burgers SA, Lebesque JV. Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with a long-term disease free survival. Int J Radiat Oncol Biol Phys 2005; 62 639-644.
   PM:15936539 

6. IF (2004): 3.302
   Borst GR, Belderbos JS, Boellaard R, Comans EF, De Jaeger K, Lammertsma AA, Lebesque JV. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 2005; 41 (11): 1533-1541.
   PM:15953716 

7. IF (2004): 3.034
   Bos LJ, van der Geer J, Van Herk M, Mijnheer BJ, Lebesque JV, Damen EM. The sensitivity of dose distributions for organ motion and set-up uncertainties in prostate IMRT. Radiother Oncol 2005; 76 (1): 18-26.
   PM:16024120 

8. IF (2004): 21.713
   Boyle P, Ariyaratne M, Bartelink H, Baselga J, Berns A, Brawley OW, Burns H, Davidov M, Dinshaw KA, Dresler C, et al. Curbing tobacco's toll starts with the professionals: World No Tobacco Day. Lancet 2005; 365 (9476): 1990-1992.
   PM:15950704 

9. IF (2004): 10.452
   Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, Van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, Van de Vijver MJ. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005; 102 (10): 3738-3743.
   PM:15701700 

10. IF (2004): 4.297
    De Jaeger K, Seppenwoolde Y, Lebesque JV, Kampinga HH. In response to drs. Anscher and Kong [letter]. Int J Radiat Oncol Biol Phys 2005; 63 (1): 308
    PM:16111602 

11. IF (2004): 9.023
    De Jaeger K. Radiotherapy. EJC Suppl 2005; 3 (3): 29-39.

     

12. De Jaeger,K.E. Radiation-induced pulmonary toxicity in non-small cell lung cancer [dissertation]. University of Amsterdam; 2005;

     

13. IF (2004): 4.297
    Deurloo KEI, Steenbakkers RJHM, Zijp LJ, De Bois JA, Nowak PJCM, Rasch CRN, Van Herk M. Quantification of shape variation of prostate and seminal vesicles during external beam radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61 (1): 228-238.
    PM:15629616

14. IF (2004): 3.302
    Dorresteijn LDA, Kappelle AC, Scholz NM, Munneke M, Scholma JT, Balm AJM, Bartelink H, Boogerd W. Increased carotid wall thickening after radiotherapy on the neck 181. Eur J Cancer 2005; 41 (7): 1026-1030.
    PM:15862751

15. IF (2004): geen
    Dorresteijn LDA, Marres HAM, Bartelink H, Kappelle LJ, Boogerd W, Kappelle AC. Radiotherapie van de hals als risicofactor voor een beroerte. Ned Tijdschr Geneeskd 2005; 149 1249-1253.

     

16. IF (2004): 5.623
    Geurts TW, Nederlof PM, van den Brekel MWM, Van't Veer LJ, De Jong D, Hart AAM, Van Zandwijk N, Klomp H, Balm AJM, van Velthuysen MLF. Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clin Cancer Res 2005; 11 (18): 6608-6614.
    PM:16166439 

17. IF (2004): 4.297
    Ghilezan MJ, Jaffray DA, Siewerdsen JH, Van Herk M, Shetty A, Sharpe MB, Zafar Jafri S, Vicini FA, Matter RC, Brabbins DS, Martinez AA. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys 2005; 62 (2): 406-417.
    PM:15890582 

18. IF (2004): 3.034
    Gillis S, De Wagter C, Bohsung J, Perrin B, Williams P, Mijnheer BJ. An inter-centre quality assurance network for IMRT verification: preliminary results of the European QUASIMODO project. Radiother Oncol 2005; 76 340-353.
    PM:16099521 

19. IF (2004): 3.302
    Haas RL, Poortmans P, De Jong D, Verheij M, van der Hulst M, de Boer JP, Bartelink H. Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. Eur J Cancer 2005; 41 (12): 1724-1730.
    PM:16039113 

20. IF (2004): geen
    Haas RL, van der Maazen RW, Meerwaldt JH, Noordijk EM, van der Linden YM. De moderne behandeling van het multipel myeloom: een richtlijn van de Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) [ingezonden] [Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)]. Ned Tijdschr Geneeskd 2005; 149 (29): 1653
    PM:16078776 

21. IF (2004): 4.297
    Heemsbergen WD, Hoogeman MS, Hart GA, Lebesque JV, Koper PC. Gastrointestinal toxicity and its relation to dose distributions in the anorectal region of prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61 (4): 1011-1018.
    PM:15752880 

22. IF (2004): geen
    Homs MY, Steyerberg EW, Eijkenboom WM, Tilanus HW, Stalpers LJ, Bartelsman JF, van Lanschot JJ, Wijrdeman HK, Mulder CJ, Reinders JG, Boot H, Aleman BMP, Kuipers EJ, Siersema PD. [Palliative treatment of esophageal cancer with dysphagia: more favourable outcome from single-dose internal brachytherapy than from the placement of a self-expanding stent; a multicenter randomised study] Palliatieve behandeling voor slokdarmkanker met passageklachten: gunstiger uitkomsten van eenmalige inwendige brachytherapie dan van plaatsing van een zelfexpanderende stent; multicentrisch, gerandomiseerd onderzoek. Ned Tijdschr Geneeskd 2005; 149 (50): 2800-2806.
    PM:16385833 

23. IF (2004): geen
    Homs MYV, Steyerberg EW, Eijkenboom WMH, Stalpers LJA, Bartelsman JFWM, van Lanschot JJB, Wijrdeman HK, Mulder CJJ, Reinders JG, Boot H, Aleman BMP, Kuipers EJ, Siersema PD. Palliatieve behandeling voor slokdarmkanker met passageklachten: gunstiger uitkomsten van eenmalige inwendige brachytherapie dan van plaatsing van een zelfexpanderende stent; multicentrisch, gerandomiserd onderzoek. Ned Tijdschr Geneeskd 2005; 149 2800-2806.

     

24. IF (2004): 2.368
    Hoogeman MS, Peeters ST, de Bois J, Lebesque JV. Absolute and relative dose-surface and dose-volume histograms of the bladder: which one is the most representative for the actual treatment? Phys Med Biol 2005; 50 (15): 3589-3597.
    PM:16030384 

25. IF (2004): 3.034
    Hoogeman MS, Van Herk M, de Bois J, Lebesque JV. Strategies to reduce the systematic error due to tumor and rectum motion in radiotherapy of prostate cancer. Radiother Oncol 2005; 74 (2): 177-185.
    PM:15734206 

26. IF (2004): 9.835
    Jansen EPM, Boot H, Verheij M, van de Velde CJ. Optimal locoregional treatment in gastric cancer. J Clin Oncol 2005; 23 (20): 4509-4517.
    PM:16002841  

27. IF (2004): 0.760
    Kaas R, Hart AAM, Rutgers EJT. The impact of the physician on the accrual to randomized clinical trials in patients with primary operable breast cancer. Breast 2005; 14 (4): 310-316.
    PM:16085238 

28. IF (2004): 3.520
    Kerst JM, Bex A, Mallo H, Dewit L, Haanen JB, Boogerd W, Teertstra HJ, de Gast GC. Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. Cancer Immunol Immunother 2005; 54 (9): 926-931.
    PM:15906025 

29. IF (2004): 2.748
    Lotz HT, Van Herk M, Betgen A, Pos F, Lebesque JV, Remeijer P. Reproducibility of the bladder shape and bladder shape changes during filling. Med Phys 2005; 32 (8): 2590-2597.
    PM:16193789 

30. IF (2004): 1.729
    Mauch P, Ng A, Aleman B, Carde P, Constine L, Diehl V, Dinshaw K, Gospodarowicz M, Hancock S, Hodgson D, Hoppe R, Liang R, Loeffler M, Specht L, Travis LB, Wirth A, Yahalom J. Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. Eur J Haematol Suppl 2005; (66): 68-76.
    PM:16007872 

31. IF (2004): 2.064
    Mutsaerts ELAR, Van Ruth S, Zoetmulder FA, Rutgers EJT, Hart AAM, Van Coevorden F. Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience. J Gastrointest Surg 2005; 9 (2): 178-186.
    PM:15694813 

32. IF (2004): 2.651
    Nieuwenhuijzen JA, Pos F, Moonen LM, Hart AAM, Horenblas S. Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol 2005; 48 (2): 239-245.
    PM:16005375 

33. IF (2004): 4.297
    Peeters STH, Hoogeman MS, Heemsbergen WD, Slot A, Tabak H, Koper PCM, Lebesque JV. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2005; 63 (4): 1142-1152.
    PM:15939547 

34. IF (2004): 4.297
    Peeters STH, Heemsbergen WD, Van Putten WLJ, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PCM. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005; 61 (4): 1019-1034.
    PM:15752881 

35. IF (2004): 3.034
    Poortmans PM, Ataman F, Davis JB, Bartelink H, Horiot JC, Pierart M, Collette L, van Tienhoven G. Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period. Radiother Oncol 2005; 76 (3): 278-284.
    PM:15919127 

36. IF (2004): 2.899
    Pos F, Moonen L. Brachytherapy in the treatment of invasive bladder cancer. Semin Radiat Oncol 2005; 15 (1): 49-54.
    PM:15662607 

37. IF (2004): 4.297
    Pos F, Horenblas S, Dom P, Moonen L, Bartelink H. Organ preservation in invasive bladder cancer: Brachytherapy, an alternative to cystectomy and combined modality treatment? Int J Radiat Oncol Biol Phys 2005; 61 (3): 678-686.
    PM:15708245 

38. IF (2004): 9.835
    Raemaekers JM, Aleman BM, Henry-Amar M. Radiotherapy in advanced-stage Hodgkin's lymphoma. J Clin Oncol 2005; 23 (1): 245-246.
    PM:15625384 

39. IF (2004): 2.899
    Rasch C, Steenbakkers R, Van Herk M. Target definition in prostate, head, and neck. Semin Radiat Oncol 2005; 15 (3): 136-145.
    PM:15983939 

40. IF (2004): 4.297
    Schwarz M, Alber M, Lebesque JV, Mijnheer BJ, Damen EMF. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2005; 62 (2): 561-570.
    PM:15890601 

41. IF (2004): 3.302
    Smit LHM, Korse CM, Hart AAM, Bonfrer JMG, Haanen JBAG, Kerst JM, Nieweg OE, de Gast GC. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 2005; 41 (3): 386-392.
    PM:15691637 

42. IF (2004): 4.297
    Smitsmans MH, de Bois J, Sonke JJ, Betgen A, Zijp LJ, Jaffray DA, Lebesque JV, Van Herk M. Automatic prostate localization on cone-beam CT scans for high precision image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63 (4): 975-984.
    PM:16253772 

43. IF (2004): 4.434
    Solin LJ, Fourquet A, Vicini FA, Taylor M, Olivotto IA, Haffty B, Strom EA, Pierce LJ, Marks LB, Bartelink H, McNeese MD, Jhingran A, Wai E, Bijker N, Campana F, Hwang WT. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 2005; 103 (6): 1137-1146.
    PM:15674853 

44. IF (2004): 3.302
    Solin LJ, Fourquet A, Vicini FA, Taylor M, Haffty B, Strom EA, Wai E, Pierce LJ, Marks LB, Bartelink H, Campana F, McNeese MD, Jhingran A, Olivotto IA, Bijker N, Hwang WT. Salvage treatment for local or local-regional recurrence after initial breast conservation treatment with radiation for ductal carcinoma in situ. Eur J Cancer 2005; 41 (12): 1715-1723.
    PM:16043350 

45. IF (2004): 2.748
    Sonke JJ, Zijp L, Remeijer P, Van Herk M. Respiratory correlated cone beam CT. Med Phys 2005; 32 (4): 1176-1186.
    PM:15895601 

46. IF (2004): 3.034
    Steenbakkers RJ, Duppen JC, Fitton I, Deurloo KE, Zijp L, Uitterhoeve AL, Rodrigus PT, Kramer GW, Bussink J, Jaeger KD, Belderbos JS, Hart AAM, Nowak PJ, Van Herk M, Rasch CRN. Observer variation in target volume delineation of lung cancer related to radiation oncologist-computer interaction: A 'Big Brother' evaluation. Radiother Oncol 2005; 77 182-190.
    PM:16256231 

47. IF (2004): 2.748
    Steggerda M, Schneider C, Van Herk M, Zijp L, Moonen L, van der Poel H. The applicability of simultaneous TRUS-CT imaging for the evaluation of prostate seed implants. Med Phys 2005; 32 (7): 2262-2270.
    PM:16121581 

48. IF (2004): 4.297
    Terhaard CHJ, Lubsen H, Rasch CRN, Levendag PC, Kaanders HHAM, Tjho-Heslinga RE, Den Ende PL, Burlage F. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 2005; 61 (1): 103-111.
    PM:15629600 

49. IF (2004): 3.034
    Valentini V, Glimelius B, Minsky BD, Van Cutsem E, Bartelink H, Beets-Tan RG, Gerard JP, Kosmidis P, Pahlman L, Picciocchi A, Quirke P, Tepper J, Tonato M, van de Velde CJ, Cellini N, Latini P. The multidisciplinary rectal cancer treatment: main convergences, controversial aspects and investigational areas which support the need for an European Consensus. Radiother Oncol 2005; 76 (3): 241-250.
    PM:16165238 

50. Van de Velde CJH, Schornagel JH, Bartelink H. Van de Velde CJH, Van Krieken JHJM, De Mulder PHM, Vermorken JB, editors.Oncologie; zevende, herziene druk. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2005; 23, Mammatumoren. p. 345-60.

     

51. IF (2004): geen
    Van den Bongard HJGD, Van Beurden M, Zoetmulder FA, Peterse JL, Dewit L. Een pati‰nt met perianale morbus Bowen: een diagnostisch en therapeutisch dilemma. Ned Tijdschr Oncol 2005; 2 188-192.

     

52. IF (2004): 2.748
    van Elmpt WJ, Nijsten SM, Mijnheer BJ, Minken AW. Experimental verification of a portal dose prediction model. Med Phys 2005; 32 (9): 2805-2818.
    PM:16266095 

53. IF (2004): geen
    Van Zandwijk N, Burgers S, Klomp HM, De Jaeger K, Visser C, Veldhuijzen J. Sneller en beter: alle diagnostiek op ‚‚n dag geeft kwaliteitsimpuls. Med Contact 2005; 39 1362-1363.

     

54. IF (2004): 4.335
    Veldman RJ, Koning GA, van Hell A, Zerp S, Vink SR, Storm G, Verheij M, Van Blitterswijk WJ. Co-formulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin. J Pharmacol Exp Ther 2005; 315 704-710.
    PM:16040815  

55. IF (2004): 1.854
    Vink SR, Schellens JHM, Van Blitterswijk WJ, Verheij M. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs 2005; 23 (4): 279-286.
    PM:16012787 

56. IF (2004): 5.742
    Wessels LFA, Reinders MJT, Hart AAM, Veenman CJ, Dai H, He YD, Van't Veer LJ. A protocol for building and evaluating predictors of disease state based on microarray data. Bioinformatics 2005; 21 (19): 3755-3762.
    PM:15817694

57. IF (2004): 2.368
    Wolthaus JWH, Van Herk M, Muller SH, Belderbos JS, Lebesque JV, De Bois JA, Rossi MMG, Damen EMF. Fusion of respiration-correlated PET and CT scans: correlated lung tumour motion in anatomical and functional scans. Phys Med Biol 2005; 50 (7): 1569-1583.
    PM:15798344

se-X=med.oncol.   (125)

1. IF (2004): 2.750
   Appels NMGM, Van Maanen MJ, Rosing H, Schellens JHM, Beijnen JH. Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19 (15): 2187-2192.
   PM:15996016 

2. IF (2004): 4.623
   Appels NMGM, Beijnen JH, Schellens JHM. Development of farnesyl transferase inhibitors: A review. Oncologist 2005; 10 (8): 565-578.
   PM:15996016 

3. IF (2004): 2.914
   Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, Van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005; 48 291-296.
   PM:15829331 

4. IF (2004): 2.914
   Baas P. Chemotherapy for malignant mesothelioma. Lung Cancer 2005; 49 Suppl 1 S61-S64
   PM:15950803 

5. IF (2004): geen
   Baas P, Sleeswijk P, Strankinga WF, van Hezik EJ, Burgers JA, Tan KY, Schouwink JH. [Problematic cases of mesothelioma reported to the Dutch Institute for Asbestos Victims: evaluation by the Mesothelioma Working Group of the Netherlands Association of Pulmonologists and Specialists in Tuberculosis] Problematische mesothelioomcasussen aangemeld bij het Instituut Asbestslachtoffers: beoordeling door de werkgroep Mesotheliomen van de Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose. Ned Tijdschr Geneeskd 2005; 149 (14): 759-763.
   PM:15835628 

6. IF (2004): geen
   Baas P, Burgers JA. Developments in the treatment of malignant mesothelioma [Ontwikkelingen in de behandeling van het maligne mesothelioom]. Ned Tijdschr Geneeskd 2005; 149 (14): 747-753.

    

7. IF (2004): geen
   Balm AJM, Schornagel JH, Rasch CRN. De rol van gelijktijdige chemotherapie en radiotherapie bij de behandeling van lokaal uitgebreide tumoren van larynx, farynx en mondholte. Ned Tijdschr Geneeskd 2005; 149 61-64.

    

8. IF (2004): 2.216
   Bardelmeijer HA, Roelofs AB, Hillebrand MJ, Beijnen JH, Schellens JHM, Tellingen OV. Metabolism of docetaxel in mice. Cancer Chemother Pharmacol 2005; 56 299-306.
   PM:15864592 

9. Beijnen JH, Rosing H. Schellens JHM, McLeod HK, Newell DR, editors.Cancer clinical pharmacology. Oxford: Oxford University Press, 2005; 1, Bioanalytical methods for anticancer drugs. p. 1-17.

    

10. IF (2004): 0.740
    Beumer JH, Schellens JHM, Beijnen JH. Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacol Res 2005; 51 (5): 391-398.
    PM:15749453 

11. IF (2004): 1.854
    Beumer JH, Rademaker-Lakhai JM, Rosing H, Lopez-Lazaro L, Beijnen JH, Schellens JHM. Trabectedin (Yondelis(TM), formerly ET-743), a mass balance study in patients with advanced cancer. Invest New Drugs 2005; 23 (5): 429-436.
    PM:16133794 

12. IF (2004): 1.854
    Beumer JH, Hillebrand MJX, Pluim D, Rosing H, Foley K, Yule SM, Schellens JHM, Beijnen JH. Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients. Invest New Drugs 2005; 23 (4): 317-330.
    PM:16012791 

13. IF (2004): 2.585
    Bex A, Nieuwenhuijzen JA, Kerst M, Pos F, Van Boven H, Meinhardt W, Horenblas S. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology 2005; 65 (2): 295-299.
    PM:15708041 

14. IF (2004): 3.520
    Bex A, Mallo H, Kerst M, Haanen J, Horenblas S, Gast GC. A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunol Immunother 2005; 54 713-719.
    PM:15627213 

15. IF (2004): 1.104
    Bex A, Kerst J, Mallo H, Van Tinteren H, Horenblas S, de Gast GC. Extended continuous oral temozolomide in patients with progressive metastatic renal cell carcinoma not responding to interferon alpha 2b. J Chemother 2005; 17 (6): 674-678.
    PM:16433200 

16. IF (2004): 13.092
    Bleiker EM, Menko FH, Taal BG, Kluijt I, Wever LD, Gerritsma MA, Vasen HFA, Aaronson NK. Screening behavior of individuals at high risk for colorectal cancer. Gastroenterology 2005; 128 (2): 280-287.
    PM:15685539 

17. IF (2004): 1.882
    Bloemendaal ALA, Verwaal VJ, Van Ruth S, Boot H, Zoetmulder FAN. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: A prospective study. Eur J Surg Oncol 2005; 31 1145-1151.
    PM:16084051 

18. IF (2004): 4.297
    Borst GR, De Jaeger K, Belderbos JSA, Burgers SA, Lebesque JV. Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients with a long-term disease free survival. Int J Radiat Oncol Biol Phys 2005; 62 639-644.
    PM:15936539 

19. IF (2004): 3.302
    Bos AM, De Vos FY, de Vries EGE, Beijnen JH, Rosing H, Mourits MJ, van der Zee AG, Gietema JA, Willemse PH. A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. Eur J Cancer 2005; 41 (4): 539-548.
    PM:15737558 

20. IF (2004): geen
    Bosch TM, Kjellberg LM, Bouwers A, Koeleman BP, Schellens JHM, Beijnen JH, Smits PH, Meijerman I. Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. Am J Pharmacogenomics 2005; 5 (2): 123-131.
    PM:15813675 

21. IF (2004): 2.052
    Brandon EF, Meijerman I, Klijn JS, den Arend D, Sparidans RW, Lazaro LL, Beijnen JH, Schellens JHM. In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anticancer Drugs 2005; 16 (9): 935-943.
    PM:16162970 

22. IF (2004): 3.056
    Brandon EF, van Ooijen RD, Sparidans RW, Lazaro LL, Heck AJ, Beijnen JH, Schellens JHM. Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry. J Mass Spectrom 2005; 40 (6): 821-831.
    PM:15892174 

23. IF (2004): 7.690
    Breedveld P, Pluim D, Cipriani G, Wielinga P, Van Tellingen O, Schinkel AH, Schellens JHM. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005; 65 (7): 2577-2582.
    PM:15805252 

24. IF (2004): 2.098
    Brouwers EE, Tibben MM, Joerger M, Van Tellingen O, Rosing H, Schellens JHM, Beijnen JH. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Anal Bioanal Chem 2005; 382 (7): 1484-1490.
    PM:15952001

25. IF (2004): geen
    Coenradi SM, Ypma PF, Schipperus MR, LeBrun PPH, Beijnen JH, Touw DJ. Pilotonderzoek naar de kinetiek van cyclofosfamide en de toxiciteit van CHOP bij ouderen. Pharm Weekbl 2005; 140 928-930.

     

26. IF (2004): geen
    Crul M, Van Zandwijk N, Beijnen JH, Schellens JHM. Klinische en preklinische farmacologie van de combinatie cisplatine en gemcitabine. Pharm Weekbl 2005; 140 369-371.

     

27. IF (2004): 4.716
    De Jong AE, Morreau H, Nagengast FM, Mathus-Vliegen EM, Kleibeuker JH, Griffioen G, Cats A, Vasen HF. Prevalence of adenomas among young individuals at average risk for colorectal cancer. Am J Gastroenterol 2005; 100 (1): 139-143.
    PM:15654793 

28. IF (2004): 2.052
    De Jonge ME, Huitema AD, Van Dam SM, Rodenhuis S, Beijnen JH. Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes. Anticancer Drugs 2005; 16 (3): 331-336.
    PM:15711186 

29. IF (2004): 2.216
    De Jonge ME, Huitema AD, Van Dam SM, Beijnen JH, Rodenhuis S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol 2005; 55 507-510.
    PM:15685452 

30. IF (2004): 2.546
    De Jonge ME, Huitema AD, Schellens JHM, Rodenhuis S, Beijnen JH. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. Br J Clin Pharmacol 2005; 59 (3): 325-334.
    PM:15752379 

31. IF (2004): 2.798
    De Jonge ME, Huitema AD, Van Dam SM, Rodenhuis S, Beijnen JH. Population Pharmacokinetics of Cyclophosphamide and Its Metabolites 4-Hydroxycyclophosphamide, 2-Dechloroethylcyclophosphamide, and Phosphoramide Mustard in a High-Dose Combination With Thiotepa and Carboplatin. Ther Drug Monit 2005; 27 (6): 756-765.
    PM:16306851 

32. IF (2004): 5.453
    De Jonge ME, Huitema AD, Schellens JHM, Rodenhuis S, Beijnen JH. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet 2005; 44 (2): 147-173.
    PM:15656695 

33. IF (2004): 5.623
    De Jonge ME, Huitema AD, Tukker AC, Van Dam SM, Rodenhuis S, Beijnen JH. Accuracy, feasibility, and clinical impact of prospective bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. Clin Cancer Res 2005; 11 (1): 273-283.
    PM:15671556 

34. IF (2004): 5.453
    De Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 2005; 44 (11): 1135-1164.
    PM:16231966 

35. IF (2004): 2.216
    De Jonge ME, Huitema AD, Holtkamp MJ, Van Dam SM, Beijnen JH, Rodenhuis S. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005; 56 (4): 370-378.
    PM:15838656 

36. IF (2004): 2.798
    De Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH. Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC). Ther Drug Monit 2005; 27 (3): 393-402.
    PM:15905813 

37. IF (2004): eruit?; 1.502
    de Maat MMR, Beijnen JH, Schellens JHM, Mulder JW. Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine. J Infect 2005; 50 (3): 262-264.
    PM:15780424 

38. IF (2004): 9.624
    Dekker LJ, Boogerd W, Stockhammer G, Dalebout JC, Siccama I, Zheng P, Bonfrer JM, Verschuuren JJ, Jenster G, Verbeek MM, Luider TM, Smitt PA. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol Cell Proteomics 2005; 4 (9): 1341-1349.
    PM:15970584 

39. IF (2004): 1.509
    Den Brok MW, Nuijen B, Hillebrand MJX, Lutz C, Opitz HG, Beijnen JH. LC-UV method development and validation for the investigational anticancer agent imexon and identification of its degradation products. J Pharm Biomed Anal 2005; 38 (4): 686-694.
    PM:15967296 

40. IF (2004): 2.052
    Den Brok MW, Nuijen B, Challa EE, Lutz C, Opitz HG, Beijnen JH. Compatibility and stability of Imexon in infusion devices and its in vitro biocompatibility. Anticancer Drugs 2005; 16 (7): 727-732.
    PM:16027520 

41. IF (2004): 2.180
    Den Brok MW, Nuijen B, Lutz C, Opitz HG, Beijnen JH. Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent Imexon using dimethyl sulfoxide as solubilising and stabilising agent. J Pharm Sci 2005; 94 (5): 1101-1114.
    PM:15793808

42. IF (2004): 0.586
    Den Brok MW, Nuijen B, Kettenes-Van Den Bosch JJ, Van Steenbergen MJ, Buluran JN, Harvey MD, Grieshaber CK, Beijnen JH. Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311 19. PDA J Pharm Sci Technol 2005; 59 (5): 285-297.
    PM:16316064 

43. IF (2004): 0.586
    Den Brok MW, Nuijen B, Meijer DM, Millan E, Manada C, Beijnen JH. Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl 76. PDA J Pharm Sci Technol 2005; 59 (4): 246-257.
    PM:16218203 

44. IF (2004): 1.509
    Den Brok MW, Nuijen B, Hillebrand MJX, Grieshaber CK, Harvey MD, Beijnen JH. Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form 169. J Pharm Biomed Anal 2005; 39 (1-2): 46-53.
    PM:15899571 

45. IF (2004): geen
    Den Brok MW, Nuijen B, Harms R, Buluran JN, Harvey MD, Grieshaber CK, Beijnen JH. Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility. J Oncol Pharm Pract 2005; 11 (1): 13-19.
    PM:16460599 

46. IF (2004): 3.302
    Dorresteijn LDA, Kappelle AC, Scholz NM, Munneke M, Scholma JT, Balm AJM, Bartelink H, Boogerd W. Increased carotid wall thickening after radiotherapy on the neck 181. Eur J Cancer 2005; 41 (7): 1026-1030.
    PM:15862751 

47. IF (2004): geen
    Dorresteijn LDA, Marres HAM, Bartelink H, Kappelle LJ, Boogerd W, Kappelle AC. Radiotherapie van de hals als risicofactor voor een beroerte. Ned Tijdschr Geneeskd 2005; 149 1249-1253.

     

48. IF (2004): 5.623
    Geurts TW, Nederlof PM, van den Brekel MWM, Van't Veer LJ, De Jong D, Hart AAM, Van Zandwijk N, Klomp H, Balm AJM, van Velthuysen MLF. Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clin Cancer Res 2005; 11 (18): 6608-6614.
    PM:16166439 

49. Gezondheidsraad, Van Zandwijk N. Protocollen asbestziekten: longkanker. Den Haag: Gezondheidsraad; 2005;

     

50. IF (2004): 0.576
    Göker E, Rodenhuis S. Early onset of oral aphthous ulcers with weekly docetaxel. Neth J Med 2005; 63 (9): 364-366.
    PM:16244385 

51. IF (2004): 3.302
    Haas RL, Poortmans P, De Jong D, Verheij M, van der Hulst M, de Boer JP, Bartelink H. Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. Eur J Cancer 2005; 41 (12): 1724-1730.
    PM:16039113 

52. IF (2004): 9.835
    Hannemann J, Oosterkamp HM, Bosch CAJ, Velds A, Wessels LFA, Loo C, Rutgers EJ, Rodenhuis S, Van de Vijver MJ. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005; 23 (15): 3331-3342.
    PM:15908647 

53. IF (2004): 9.835
    Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, Van Tinteren H, Postmus PE, Golding RP, Biesma B, Schramel FJ, Van Zandwijk N, Lammertsma AA, Hoekstra OS. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005; 23 (33): 8362-8370.
    PM:16293866 

54. IF (2004): geen
    Homs MYV, Steyerberg EW, Eijkenboom WMH, Stalpers LJA, Bartelsman JFWM, van Lanschot JJB, Wijrdeman HK, Mulder CJJ, Reinders JG, Boot H, Aleman BMP, Kuipers EJ, Siersema PD. Palliatieve behandeling voor slokdarmkanker met passageklachten: gunstiger uitkomsten van eenmalige inwendige brachytherapie dan van plaatsing van een zelfexpanderende stent; multicentrisch, gerandomiserd onderzoek. Ned Tijdschr Geneeskd 2005; 149 2800-2806.

     

55. IF (2004): geen
    Jager A, Linn SC. Behandeling van gemetastaseerd mammacarcinoom na voorbehandeling met anthracyclines en taxanen. Ned Tijdschr Oncol 2005; 2 232-239.

     

56. IF (2004): 9.835
    Jansen EPM, Boot H, Verheij M, van de Velde CJ. Optimal locoregional treatment in gastric cancer. J Clin Oncol 2005; 23 (20): 4509-4517.
    PM:16002841 

57. IF (2004): 1.283
    Joerger M, Koeberle D, Neumann HPH, Gillessen S. Von Hippel-Lindau disease--a rare disease important to recognize. Onkologie 2005; 28 (3): 159-163.
    PM:15772467 

58. IF (2004): 2.216
    Joerger M, Huitema AD, Meenhorst PL, Schellens JHM, Beijnen JH. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer Chemother Pharmacol 2005; 55 488-496.
    PM:15726371 

59. IF (2004): geen
    Juffermans NP, Jager A, Kersten MJ, van Oers MH, Hommes DW. [Epstein-Barr virus-related lymphomas in patients with inflammatory bowel disease] Epstein-Barr-virus-gerelateerde lymfomen bij patienten met inflammatoire darmziekte. Ned Tijdschr Geneeskd 2005; 149 (33): 1859-1863.
    PM:16128185 

60. IF (2004): 2.052
    Kappelhoff BS, Huitema AD, Mairuhu AT, Schellens JHM, Beijnen JH. No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. Anticancer Drugs 2005; 16 (6): 627-630.
    PM:15930890 

61. IF (2004): 3.520
    Kerst JM, Bex A, Mallo H, Dewit L, Haanen JB, Boogerd W, Teertstra HJ, de Gast GC. Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. Cancer Immunol Immunother 2005; 54 (9): 926-931.
    PM:15906025 

62. IF (2004): geen
    Koning CEE, Van Zandwijk N. Twee pati‰nten met gevorderd niet-kleincellig longcarcinoom (stadium IIIB) en toch een zeer goede reactie op gecombineerde chemo- en radiotherapie. Ned Tijdschr Geneeskd 2005; 149 1289-1293.

     

63. IF (2004): 1.069
    Kuppens IE, Van Maanen MJ, Rosing H, Schellens JHM, Beijnen JH. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr 2005; 19 355-361.
    PM:15586372 

64. IF (2004): 1.935
    Kuppens IELM, Breedveld P, Beijnen JH, Schellens JHM. Modulation of oral drug bioavailability. Cancer Invest 2005; 23 443-464.
    PM:16193644 

65. IF (2004): 2.216
    Kuppens IELM, Bosch TM, Van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, Schellens JHM. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol 2005; 55 (1): 72-78.
    PM:15316750 

66. Lakhai WS, Beijnen JH, Schellens JHM. Schellens JHM, McLeod HL, Newell DR, editors.Cancer clinical pharmacology. Oxford: Oxford University Press, 2005; 14, Novel tyrosine kinase inhibitors: focus on imatinib nd gefitinib. p. 198-215.

     

67. IF (2004): 9.835
    Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23 (3): 576-584.
    PM:15659504 

68. IF (2004): 2.914
    Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, Van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, Fitzgerald P, Aristides M, Schiller JH. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005; 47 (1): 69-80.
    PM:15603856 

69. IF (2004): geen
    Linn SC, Helgason HH, Oosterkamp HM. De MATADOR-studie: multicenter fase-III-onderzoek naar chemotherapie op maat bij het mammacarcinoom. Ned Tijdschr Oncol 2005; 2 193-198.

     

70. IF (2004): 9.835
    Luiten RM, Kueter EW, Mooi W, Gallee MPW, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC. Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients. J Clin Oncol 2005; 23 8978-8991.
    PM:16260696 

71. IF (2004): 2.914
    Mathy A, Baas P, Dalesio O, Van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005; 50 (1): 83-86.
    PM:15951053 

72. IF (2004): geen
    Meij V, Zuetenhorst JM, Van Hillegersberg R, Kroger R, Prevoo W, Van Coevorden F, Taal BG. Local treatment in unresectable hepatic metastases of carcinoid tumors: Experiences with hepatic artery embolization and radiofrequency ablation. World J Surg Oncol 2005; 3 (1): 75
    PM:16293186 

73. Milano G, Schellens JHM. Schellens JHM, McLeod HL, Newell DR, editors.Cancer clinical pharmacology. Oxford: Oxford University Press, 2005; 5, Pyrimidine antimetabolites. p. 51-62.

     

74. IF (2004): 1.758
    Moser EC, Noordijk EM, Carde P, Tirelli U, Baars JW, Thomas J, Bron D, Meerwaldt JH, Van Glabbeke M, Raemaekers JM, Kluin-Nelemans HC. Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma 2005; 6 (2): 122-130.
    PM:16231850 

75. Neering H, Kroon BBR. Van de Velde CJH, Van Krieken JHJM, De Mulder PHM, Vermorken JB, editors.Oncologie; zevende, herziene druk. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2005; 22, Huidtumoren. p. 331-43.

     

76. IF (2004): 3.713
    Nieuwenhuijzen JA, Horenblas S, Bex A, Kerst JM, Schornagel JH, Van Tinteren H, Meinhardt W. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol 2005; 174 80-85.
    PM:15947583 

77. IF (2004): geen
    Nijland HMJ, Huitema ADR, Otten JMMB, Schellens JHM. Overzicht van interacties tussen oncolytica en orale anticoagulantia: ernstige gevolgen. Pharm Weekbl 2005; 140 1442-1447.

     

78. IF (2004): geen
    Nijland HMJ, Huitema ADR, Beijnen JH, Otten JMMB, Schellens JHM. Review of interactions between oncolytic agents and oral anticoagulants - Severe consequences [Overzicht van interacties tussen oncolytica en orale anticoagulantia - Ernstige gevolgen]. Pharm Weekbl 2005; 140 (46): 1442-1447.

     

79. IF (2004): geen
    Nuijen B, Den Brok MWJ, Manada C, Bult A, Beijnen JH. Farmaceutische ontwikkeling van nieuwe antikanker middelen. Liever geen water bij producten van mariene oorsprong. Pharm Weekbl 2005; 140 104-109.

     

80. IF (2004): 2.216
    Press RR, Buckle T, Beijnen JH, Van Tellingen O. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. Cancer Chemother Pharmacol 2005; 1-7.
    PM:16163538 

81. IF (2004): 2.052
    Rademaker-Lakhai JM, Crul M, Pluim D, Sparidans RW, Baas P, Beijnen JH, Van Zandwijk N, Schellens JH. Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Anticancer Drugs 2005; 16 (9): 1029-1036.
    PM:16162981 

82. IF (2004): 5.623
    Rademaker-Lakhai JM, Horenblas S, Meinhardt W, Stokvis E, de Reijke TM, Jimeno JM, Lopez-Lazaro L, Lopez Martin JA, Beijnen JH, Schellens JHM. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin Cancer Res 2005; 11 (5): 1854-1862.
    PM:15756010 

83. IF (2004): 4.335
    Rea DW, Nortier JW, Ten Bokkel Huinink WW, Falk S, Richel DJ, Maughan T, Groenewegen G, Smit JM, Steven N, Bakker JM, Semiond D, Kerr DJ, Punt CJ. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 2005; 16 (7): 1123-1132.
    PM:15939714 

84. IF (2004): 5.973
    Reijneveld JC, Brandsma D, Boogerd W, Bonfrer JGM, Kalmijn S, Voest EE, Geurts-Moespot A, Visser MC, Taphoorn MJ. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 2005; 65 (7): 1120-1122.
    PM:16217072 

85. Rodenhuis S. Van de Velde CJH, Van Krieken JHJM, De Mulder PHM, Vermorken JB, editors.Oncologie; zevende, herziene druk. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2005; 4, Paraneoplastische syndromen. p. 73-82.

     

86. IF (2004): 3.302
    Rodenhuis S. Is high-dose chemotherapy dead? [Editorial comment]. Eur J Cancer 2005; 41 (1): 9-11.
    PM:15617985 

87. Roodenburg JLN, Van Laer CG, Robinson PH, et al. Van de Velde CJH, Van Krieken JHJM, De Mulder PHM, Vermorken JB, editors.Oncologie; zevende, herziene druk. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2005; 14, Hoofd-halstumoren. p. 207-50.

     

88. IF (2004): eruit
    Rook EJ, Hillebrand MJ, Rosing H, van Ree JM, Beijnen JH. The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 824 (1-2): 213-221.
    PM:16103023 

89. IF (2004): geen
    Schellens JHM. Challenges of oral chemotherapy. Clin Adv Hematol Oncol 2005; 3 (2): 99-100.
    PM:16166975 

90. IF (2004): geen
    Schellens JHM. Misleidende reclame voor OxyContin. Pharm Weekbl 2005; 140 196

     

91. Schellens JHM. Schellens JHM, McLeod HL, Newell DR, editors.Cancer clinical pharmacology. Oxford: Oxford University Press, 2005; 3, Clinical implications and mechanisms of variability in the response to anticancer agents. p. 30-40.

     

92. IF (2004): 2.216
    Schoemaker NE, Kuppens IELM, Ten Bokkel Huinink WW, Lefebvre P, Beijnen JH, Assadourian S, Sanderink GJ, Schellens JHM. Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. Cancer Chemother Pharmacol 2005; 55 (3): 263-270.
    PM:15592838 

93. IF (2004): 3.195
    Schreuder MI, Hoeve MA, Groothuis L, Boot H, Boerrigter LH, De Jong D, Veenendaal RA, Jansen JH, Van Krieken JHJM. Monitoring gastric lymphoma in peripheral blood by quantitative IgH allele-specific oligonucleotide real-time PCR and API2-MALT1 PCR. Br J Haematol 2005; 131 (5): 619-623.
    PM:16351637 

94. IF (2004): 5.080
    Sesink ALA, Arts ICW, de Boer VCJ, Breedveld P, Schellens JHM, Hollman PC, Russel FGM. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol Pharmacol 2005; 67 (6): 1999-2006.
    PM:15749994 

95. IF (2004): 3.742
    Siegel-Lakhai WS, Crul M, Zhang S, Sparidans RW, Pluim D, Howes A, Solanki B, Beijnen JH, Schellens JHM. Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra((R)), R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. Br J Cancer 2005; 93 1222-1229.
    PM:16251868 

96. IF (2004): 4.623
    Siegel-Lakhai WS, Beijnen JH, Schellens JHM. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 2005; 10 (8): 579-589.
    PM:16177282 

97. Siegel-Lakhai,W.S. Clinical pharmacology of molecular targeted anticancer therapy [Klinische farmacologie van nieuwe doelgerichte antikanker therapeutica] [dissertation]. University Utrecht; 2005;

     

98. IF (2004): 2.750
    Silvertand LH, Vazvaei F, Weigl P, Rosing H, Hillebrand MJX, Van Maanen MJ, Beijnen JH. Simultaneous quantification of fludarabine and cyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19 (24): 3673-3680.
    PM:16287039

99. IF (2004): 3.302
    Smit LHM, Korse CM, Hart AAM, Bonfrer JMG, Haanen JBAG, Kerst JM, Nieweg OE, de Gast GC. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 2005; 41 (3): 386-392.
    PM:15691637 

100. Smit,L.H.M. Clinical relevance of serum S-100B for melanoma patients [Klinische relevantie van serum S-100B bij melanoompati‰nten] [dissertation]. Utrecht University; 2005;

      

101. IF (2004): geen
     Smit LHM, Nieweg OE, de Gast GC, Vald‚s Olmos RA, Comans EFI, Kroon BBR. Metastasectomie bij stadium IV melanoom, te overwegen bij zorgvuldig geselecteerde pati‰nten. Ned Tijdschr Oncol 2005; 2 147-152.

      

102. IF (2004): 2.750
     Stokvis E, Rosing H, Beijnen JH. Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not? Rapid Commun Mass Spectrom 2005; 19 (3): 401-407.
     PM:15645520 

103. IF (2004): 8.749
     Stokvis E, Rosing H, Beijnen JH. Liquid chromatography-mass spectrometry for the quantitative bioanalysis of anticancer drugs. Mass Spectrom Rev 2005; 24 887-917.
     PM:15599948 

104. IF (2004): geen
     Taal BG. Diagnosis and treatment in intestinal carcinoid tumors. Curr Gastroenterol Rep 2005; 7 (1): 1-3.
     PM:15701288 

105. IF (2004): geen
     Taal BG, Smits M. Developments in diagnosis and treatment of metastatic midgut carcinoid tumors. A review. Minerva Gastroenterol Dietol 2005; 51 (4): 335-344.
     PM:16282961 

106. IF (2004): 2.054
     Triesscheijn M, Ruevekamp M, Aalders M, Baas P, Stewart FA. Outcome of mTHPC Mediated Photodynamic Therapy is Primarily Determined by the Vascular Response. Photochem Photobiol 2005; 81 (5): 1161-1167.
     PM:15934792 

107. IF (2004): geen
     Van't Veer LJ, Rodenhuis S, Van de Vijver MJ. Prognostische betekenis van het genexpressieprofiel van mammatumoren, bepaald met DNA-microarrays. Ned Tijdschr Geneeskd 2005; 149 638-646.

      

108. Van de Velde CJH, Schornagel JH, Bartelink H. Van de Velde CJH, Van Krieken JHJM, De Mulder PHM, Vermorken JB, editors.Oncologie; zevende, herziene druk. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2005; 23, Mammatumoren. p. 345-60.

      

109. IF (2004): 3.836
     van Herwaarden AE, Smit JW, Sparidans RW, Wagenaar E, van der Kruijssen CMM, Schellens JHM, Beijnen JH, Schinkel AH. Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. Drug Metab Dispos 2005; 33 (7): 892-895.
     PM:15845749 

110. IF (2004): 1.854
     van Kesteren C, Zandvliet AS, Karlsson MO, Mathot RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roche HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JHM. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam 355. Invest New Drugs 2005; 23 (3): 225-234.
     PM:15868378 

111. IF (2004): geen
     van Meerbeeck JP, Koning CC, Tjan-Heijnen VC, Boekema AG, Kaandorp CJ, Burgers JA. [Guideline on 'non-small cell lung carcinoma; staging and treatment'] Richtlijn 'Niet-kleincellig longcarcinoom; stadiering en behandeling'. Ned Tijdschr Geneeskd 2005; 149 (2): 72-77.
     PM:15688837 

112. IF (2004): 3.096
     Van Schil P, Van Meerbeeck J, Kramer G, Splinter T, Legrand C, Giaccone G, Manegold C, Van Zandwijk N. Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J 2005; 26 (2): 192-197.
     PM:16055865 

113. IF (2004): 1.667
     Van Tellingen O, Bardelmeijer HA, Buckle T, Ouwehand M, Beijnen JH, Schellens JHM. Cannulation of the jugular vein in mice 366. Lab Anim 2005; 39 (1): 130
     PM:15703135 

114. IF (2004): 2.955
     van Velthuysen MLF, Taal BG, van der Hoeven JJ, Peterse JL. Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma. Histopathology 2005; 46 (2): 153-157.
     PM:15693887 

115. IF (2004): 3.302
     Van Zandwijk N. Chemoprevention in lung carcinogenesis - An overview. Eur J Cancer 2005; 41 (13): 1990-2002.
     PM:16112567 

116. IF (2004): geen
     Van Zandwijk N, Burgers S, Klomp HM, De Jaeger K, Visser C, Veldhuijzen J. Sneller en beter: alle diagnostiek op ‚‚n dag geeft kwaliteitsimpuls. Med Contact 2005; 39 1362-1363.

      

117. Van Zandwijk N, Mulshine JL. Hirsch FR, Bunn PA, Mulshine JL, editors.Textbook of prevention and detection of early lung cancer. London/New York: Taylor & Francis, 2005;Chemoprevention. p. 341-59.

      

118. IF (2004): 4.035
     Verwaal VJ, Van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FAN. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12 (1): 65-71.
     PM:15827780 

119. Verweij J, Schellens JHM. Van de Velde CJH, Van Krieken JHJM, De Mulder PHM, Vermorken JB, editors.Oncologie; zevende, herziene druk. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2005; 6, Klinische onderzoeksmethodologie in de oncologie. p. 125-30.

      

120. Wiggers T, Marijnen CAM, Punt CIA. Van de Velde CJH, Van Krieken JHJM, De Mulder PHM, Vermorken JB, editors.Oncologie; zevende, herziene druk. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2005; 19, Tumoren van dunne en dikke darm. p. 297-308.

      

121. IF (2004): 1.144
     Wuermli L, Joerger M, Henz S, Schmid HP, Riesen WF, Thomas G, Krek W, Cerny T, Gillessen S. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 2005; 8 (4): 316-320.
     PM:16158078 

122. IF (2004): 10.452
     Zelcer N, van de Wetering K, Hillebrand M, Sarton E, Kuil A, Wielinga PR, Tephly T, Dahan A, Beijnen JH, Borst P. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci U S A 2005; 102 (20): 7274-7279.
     PM:15886284 

123. IF (2004): 2.914
     Zielinski CC, Beinert T, Crawford J, Fischer JR, Georgoulias V, Gridelli C, Hirsch FR, Jassem J, Herold C, Kosmidis P, Van Zandwijk N. Consensus on medical treatment of non-small-cell lung cancer - update 2004. Lung Cancer 2005; 50 129-137.

      

124. IF (2004): 4.623
     Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist 2005; 10 (2): 123-131.
     PM:15709214 

125. Zuetenhorst,J.M. Diagnostic and treatment modalities in carcinoid tumours [dissertation]. University of Amsterdam; 2005;

se-XI=surg.oncol.       (107)

1. IF (2004): 1.882
   Balm AJM, Lohuis PJ, Copper MP. Surgical technique-unwrapping the neck node levels around a sternocleidomastoid muscle bar: A systematic way of performing (modified) radical neck dissection. Eur J Surg Oncol 2005; 31 1216-1221.
   PM:16171967 

2. IF (2004): geen
   Balm AJM, Schornagel JH, Rasch CRN. De rol van gelijktijdige chemotherapie en radiotherapie bij de behandeling van lokaal uitgebreide tumoren van larynx, farynx en mondholte. Ned Tijdschr Geneeskd 2005; 149 61-64.

    

3. IF (2004): 2.585
   Bex A, Nieuwenhuijzen JA, Kerst M, Pos F, Van Boven H, Meinhardt W, Horenblas S. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology 2005; 65 (2): 295-299.
   PM:15708041 

4. IF (2004): 3.520
   Bex A, Mallo H, Kerst M, Haanen J, Horenblas S, Gast GC. A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunol Immunother 2005; 54 713-719.
   PM:15627213 

5. IF (2004): 1.104
   Bex A, Kerst J, Mallo H, Van Tinteren H, Horenblas S, de Gast GC. Extended continuous oral temozolomide in patients with progressive metastatic renal cell carcinoma not responding to interferon alpha 2b. J Chemother 2005; 17 (6): 674-678.
   PM:16433200

6. Bex,A. Timing of nephrectomy and systemic therapy in primary metastatic renal cell carcinoma [dissertation]. Universiteit Utrecht; 2005;

    

7. IF (2004): geen
   Bindels EMJ, van den Brekel MWM. Development of a conditional mouse model for head and neck squamous cell carcinoma. Adv Otorhinolaryngol 2005; 62 1-11.
   PM:15608413 

8. IF (2004): 1.882
   Bloemendaal ALA, Verwaal VJ, Van Ruth S, Boot H, Zoetmulder FAN. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: A prospective study. Eur J Surg Oncol 2005; 31 1145-1151.
   PM:16084051 

9. IF (2004): 2.220
   Buwalda J, Freling NJ, Blank LE, Balm AJM, Bras J, Voute PA, Caron HN, Schouwenburg PF, Merks JHM. AMORE protocol in pediatric head and neck rhabdomyosarcoma: descriptive analysis of failure patterns. Head Neck 2005; 27 (5): 390-396.
   PM:15825203 

10. IF (2004): 0.900
    de Weerd L, Woerdeman LA, Hage JJ. The lateral thoracodorsal flap as a salvage procedure for partial transverse rectus abdominis myocutaneous or deep inferior epigastric perforator flap loss in breast reconstruction. Ann Plast Surg 2005; 54 (6): 590-594.
    PM:15900140 

11. IF (2004): 3.302
    Deurloo EE, Peterse JL, Rutgers EJT, Besnard APE, Muller SH, Gilhuijs KGA. Additional breast lesions in patients eligible for breast-conserving therapy by MRI: impact on preoperative management and potential benefit of computerised analysis 176. Eur J Cancer 2005; 41 (10): 1393-1401.
    PM:15913987 

12. IF (2004): 3.302
    Dorresteijn LDA, Kappelle AC, Scholz NM, Munneke M, Scholma JT, Balm AJM, Bartelink H, Boogerd W. Increased carotid wall thickening after radiotherapy on the neck 181. Eur J Cancer 2005; 41 (7): 1026-1030.
    PM:15862751 

13. IF (2004): 3.653
    Everts B, Van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 2005; 12 (2): 141-161.
    PM:15472714 

14. IF (2004): 5.623
    Geurts TW, Nederlof PM, van den Brekel MWM, Van't Veer LJ, De Jong D, Hart AAM, Van Zandwijk N, Klomp H, Balm AJM, van Velthuysen MLF. Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clin Cancer Res 2005; 11 (18): 6608-6614.
    PM:16166439 

15. IF (2004): 0.900
    Hage JJ, Woerdeman LAE, Smeulders MJ. The Truly Distal Lateral Arm Flap: Rationale and Risk Factors of a Microsurgical Workhorse in 30 Patients. Ann Plast Surg 2005; 54 (2): 153-159.
    PM:15655465 

16. IF (2004): geen
    Hage JJ, Karim RB. Oncological reconstructive surgery: an ongoing challenge. Cancer Control 2005; 1 5-8.

     

17. IF (2004): 9.835
    Hannemann J, Oosterkamp HM, Bosch CAJ, Velds A, Wessels LFA, Loo C, Rutgers EJ, Rodenhuis S, Van de Vijver MJ. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005; 23 (15): 3331-3342.
    PM:15908647 

18. IF (2004): geen
    Hilgers FJM, Vanca PHJ, Vis R. Safe and efficient use of flexible nasopharyngoscopes by applying sterile, disposable protection sheaths [Veilig en doelmatig gebruik van flexibele nasofaryngoscopen door toepassing van steriele, disposable beschermhoezen]. Ned Tijdschr KNO-Heelkd 2005; 11 (3): 131-136.

     

19. IF (2004): geen
    Hilgers FJM. The otolaryngologist and medical rehabilitation [De KNO-arts en revalidatie (geneeskunde)]. Ned Tijdschr KNO-Heelkd 2005; 11 (1): 5-7.

     

20. IF (2004): geen
    Horenblas S, Kroon BK. [The foreskin and squamous-cell carcinoma of the penis] De voorhuid en het plaveiselcelcarcinoom van de penis. Ned Tijdschr Geneeskd 2005; 149 (44): 2450-2453.
    PM:16285359 

21. IF (2004): geen
    Horenblas S. Is brachytherapy an effective treatment for penile carcinoma? Nat Clin Pract Urol 2005; 2 (10): 474-475.
    PM:16474618 

22. IF (2004): geen
    Horenblas S, Kroon BK. The foreskin and squamous-cell carcinoma of the penis [De voorhuid en het plaveiselcel-carcinoom van de penis]. Ned Tijdschr KNO-Heelkd 2005; 13 (8): 198-200.

     

23. IF (2004): 3.302
    In der Maur CD, Klokman WJ, Van Leeuwen FE, Tan IB, Rutgers EJT, Balm AJM. Increased risk of breast cancer development after diagnosis of salivary gland tumour. Eur J Cancer 2005; 41 (9): 1311-1315.
    PM:15939266 

24. IF (2004): 3.580
    Jansen MC, van Duijnhoven FH, Van Hillegersberg R, Rijken A, Van Coevorden F, van der Sijp J, Prevoo W, van Gulik TM. Adverse effects of radiofrequency ablation of liver tumours in the Netherlands. Br J Surg 2005; 92 1248-1254.
    PM:15997440 

25. IF (2004): 2.220
    Janssen HL, Balm AJM, Haustermans KM, Begg AC. Hypoxia in head and neck tumors: how much, how important? Head Neck 2005; 27 622-638.
    PM:15952198

26. IF (2004): 0.760
    Kaas R, Hart AAM, Rutgers EJT. The impact of the physician on the accrual to randomized clinical trials in patients with primary operable breast cancer. Breast 2005; 14 (4): 310-316.
    PM:16085238 

27. IF (2004): 1.882
    Kapma MR, Vrouenraets BC, Nieweg OE, van Geel AN, Noorda EM, Eggermont AMM, Kroon BBR. Major amputation for intractable extremity melanoma after failure of isolated limb perfusion. Eur J Surg Oncol 2005; 31 (1): 95-99.
    PM:15642433 

28. IF (2004): 3.520
    Kerst JM, Bex A, Mallo H, Dewit L, Haanen JB, Boogerd W, Teertstra HJ, de Gast GC. Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. Cancer Immunol Immunother 2005; 54 (9): 926-931.
    PM:15906025

29. IF (2004): geen
    Klein S, Hage JJ, de Weerd L. [Perforator flaps--the evolution of a reconstructive surgical technique] Perforatorlappen--de evolutie van een reconstructieve chirurgische techniek. Ned Tijdschr Geneeskd 2005; 149 (43): 2392-2398.
    PM:16277128 

30. IF (2004): 0.812
    Klein S, Hage JJ, Woerdeman LA. Donor-site necrosis following fibula free-flap transplantation: a report of three cases. Microsurgery 2005; 25 (7): 538-542.
    PM:16184523 

31. IF (2004): 2.000
    Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linhorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, De Koning HJ, Rutgers T, Klijn JG. Efficacy of Magnetic Resonance Imaging and Mammography for Breast Cancer Screening in Women With a Familial or Genetic Predisposition. Obstet Gynecol Surv 2005; 60 (2): 107-109.
    PM:15671899 

32. IF (2004): 1.582
    Kroon BK, Vald‚s Olmos RA, Van der Poel HG, Nieweg OE, Horenblas S. Prepubic sentinel node location in penile carcinoma. Clin Nucl Med 2005; 30 (10): 649-650.
    PM:16166835 

33. IF (2004): 1.758
    Kroon BK, Horenblas S, Nieweg OE. Contemporary management of penile squamous cell carcinoma. J Surg Oncol 2005; 89 (1): 43-50.
    PM:15611938 

34. IF (2004): 2.089
    Kroon BK, Horenblas S, Deurloo EE, Nieweg OE, Teertstra HJ. Ultrasonography-guided fine-needle aspiration cytology before sentinel node biopsy in patients with penile carcinoma. BJU Int 2005; 95 (4): 517-521.
    PM:15705071 

35. IF (2004): 3.713
    Kroon BK, Horenblas S, Lont AP, Tanis PJ, Gallee MPW, Nieweg OE. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol 2005; 173 (3): 816-819.
    PM:15711276

36. IF (2004): 3.713
    Kroon BK, Lont AP, Vald‚s Olmos RA, Nieweg OE, Horenblas S. Morbidity of dynamic sentinel node biopsy in penile carcinoma. J Urol 2005; 173 (3): 813-815.
    PM:15711275 

37. IF (2004): 3.713
    Kroon BK, Vald‚s Olmos RA, Van Tinteren H, Nieweg OE, Horenblas S. Reproducibility of lymphoscintigraphy for lymphatic mapping in patients with penile carcinoma. J Urol 2005; 174 (6): 2214-2217.
    PM:16280766 

38. IF (2004): geen
    Kroon BK, Horenblas S, Nieweg OE. [Less mutilating treatment of penile carcinoma] Minder mutilerende behandeling van het peniscarcinoom. Ned Tijdschr Geneeskd 2005; 149 (44): 2465-2469.
    PM:16285363 

39. IF (2004): 3.935
    Kroon BK, Vald‚s Olmos RA, Nieweg OE, Horenblas S. Non-visualization of sentinel lymph nodes in penile carcinoma. Eur J Nucl Med Mol Imaging 2005; 32 (9): 1096-1099.
    PM:15875177 

40. IF (2004): 2.651
    Kroon BK, Horenblas S, Meinhardt W, Van der Poel HG, Bex A, Van Tinteren H, Valdes Olmos RA, Nieweg OE. Dynamic sentinel node biopsy in penile carcinoma: evaluation of 10 years experience. Eur Urol 2005; 47 (5): 601-606.
    PM:15826750 

41. Lohuis PJ, Balm AJM, Nolst Trenit‚ GJ. Nolst Trenit‚ GJ, editors.Rhinoplasty, a practical guide to functional and aesthetic surgery of the nose; 3rd edition. The Hague: Kugler Publications, 2005;Reconstruction of skin cancer defects of the nose. p. 329-54.

     

42. IF (2004): 1.872
    Loonen MP, Hage JJ, Kon M. Who benefits from peer review? An analysis of the outcome of 100 requests for review by Plastic and Reconstructive Surgery. Plast Reconstr Surg 2005; 116 (5): 1461-1472.
    PM:16217496

43. IF (2004): geen
    Lopuha„ CE, Copper MP, Balm AJM. Obstructive sleep apnea syndrome in a 7-year-old boy [Obstructief slaapapneusyndroom op jeugdige leeftijd]. Ned Tijdschr KNO-Heelkd 2005; 11 (3): 143-145.

     

44. IF (2004): 9.835
    Luiten RM, Kueter EW, Mooi W, Gallee MPW, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC. Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients. J Clin Oncol 2005; 23 8978-8991.
    PM:16260696 

45. IF (2004): 1.408
    Luppino FS, Pameijer FA, Balm AJM. Radiology quiz case 2. Laryngeal plasmacytoma in a patient with known multiple myeloma (MM). Arch Otolaryngol Head Neck Surg 2005; 131 (1): 74
    PM:15655194 

46. IF (2004): 9.835
    Madalinska JB, Hollenstein J, Bleiker E, Van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. Quality-of-Life Effects of Prophylactic Salpingo-Oophorectomy Versus Gynecologic Screening Among Women at Increased Risk of Hereditary Ovarian Cancer. J Clin Oncol 2005; 23 6890-6898.
    PM:16129845 

47. IF (2004): geen
    Meij V, Zuetenhorst JM, Van Hillegersberg R, Kroger R, Prevoo W, Van Coevorden F, Taal BG. Local treatment in unresectable hepatic metastases of carcinoid tumors: Experiences with hepatic artery embolization and radiofrequency ablation. World J Surg Oncol 2005; 3 (1): 75
    PM:16293186 

48. IF (2004): 1.882
    Meijnen P, Peterse JL, Oldenburg HSA, Woerdeman LAE, Rutgers EJT. Changing patterns in diagnosis and treatment of ductal carcinoma in situ of the breast. Eur J Surg Oncol 2005; 31 (8): 833-839.
    PM:15923104 

49. IF (2004): geen
    Meinhardt W, Naderi N. Review of HIV and AIDS related urologic disorders [Overzicht van aan HIV en AIDS gerelateerde urologische afwijkingen]. Ned Tijdschr Urol 2005; 13 (4): 96-100.

     

50. IF (2004): 5.907
    Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Wang HJ. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005; 242 (3): 302-311.
    PM:16135917 

51. IF (2004): 2.064
    Mutsaerts ELAR, Van Ruth S, Zoetmulder FA, Rutgers EJT, Hart AAM, Van Coevorden F. Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience. J Gastrointest Surg 2005; 9 (2): 178-186.
    PM:15694813 

52. Neering H, Kroon BBR. Van de Velde CJH, Van Krieken JHJM, De Mulder PHM, Vermorken JB, editors.Oncologie; zevende, herziene druk. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2005; 22, Huidtumoren. p. 331-43.

     

53. IF (2004): geen
    Nieuwenhuijzen J, Meinhardt W, Horenblas S. Oncological and functional results after sexuality-sparing cystectomy and neobladder [Oncologische en functionele resultaten na seksualiteitsparende cystectomie en neoblaas]. Ned Tijdschr Urol 2005; 13 (6): 140-144.

     

54. IF (2004): 2.651
    Nieuwenhuijzen JA, Pos F, Moonen LM, Hart AAM, Horenblas S. Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol 2005; 48 (2): 239-245.
    PM:16005375 

55. IF (2004): 3.713
    Nieuwenhuijzen JA, Horenblas S, Bex A, Kerst JM, Schornagel JH, Van Tinteren H, Meinhardt W. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol 2005; 174 80-85.
    PM:15947583 

56. IF (2004): 3.713
    Nieuwenhuijzen JA, Meinhardt W, Horenblas S. Clinical outcomes after sexuality preserving cystectomy and neobladder (prostate sparing cystectomy) in 44 patients. J Urol 2005; 173 (4): 1314-1317.
    PM:15758788 

57. IF (2004): 3.935
    Nieweg OE, Van Rijk MC, Vald‚s Olmos RA, Hoefnagel CA. Sentinel node biopsy and selective lymph node clearance--impact on regional control and survival in breast cancer and melanoma 281. Eur J Nucl Med Mol Imaging 2005; 32 (6): 631-634.
    PM:15875179 

58. IF (2004): geen
    Nieweg OE, Kroon BBR. Richtlijn 'melanoom' (3e herziening) 3. Ned Tijdschr Geneeskd 2005; 149 (50): 2821-2822.
    PM:16385838 

59. IF (2004): 2.083
    Olivier RI, Lubsen-Brandsma LA, Van Boven H, Van Beurden M. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense? Gynecol Oncol 2005; 96 (2): 439-443.
    PM:15661233 

60. IF (2004): 2.083
    Olivier RI, Van Beurden M. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations" [letter-reply]. Gynecol Oncol 2005; 99 (2): 520-521.
    PM:16188301 

61. IF (2004): geen
    Olivier RI, Van Beurden M, Lubsen-Brandsma MAC. Klinische afwegingen bij vrouwen met een verhoogd risico op ovariumcarcinoom. Ned Tijdschr Oncol 2005; 2 105-109.

     

62. IF (2004): 0.870
    Op de Coul BM, Ackerstaff AH, Van As-Brooks CJ, van den Hoogen FJ, Meeuwis CA, Manni JJ, Hilgers FJM. Compliance, quality of life and quantitative voice quality aspects of hands-free speech. Acta Otolaryngol 2005; 125 (6): 629-637.
    PM:16076712 

63. IF (2004): 0.794
    Op de Coul BMR, Ackerstaff AH, van As CJ, van den Hoogen FJA, Meeuwis CA, Manni JJ, Hilgers FJM. Quality of life assessment in laryngectomized individuals: do we need additions to standard questionnaires in specific clinical research projects? Clin Otolaryngol 2005; 30 (2): 169-175.
    PM:15839870 

64. IF (2004): 3.643
    Oudejans JJ, Harijadi A, Cillessen SA, Busson P, Tan IB, Dukers DF, Vos W, Hariwiyanto B, Middeldorp J, Meijer CJ. Absence of caspase 3 activation in neoplastic cells of nasopharyngeal carcinoma biopsies predicts rapid fatal outcome. Mod Pathol 2005; 18 877-885.
    PM:15803189 

65. IF (2004): 1.576
    Plaat RE, de Bree R, Kuik DJ, van den Brekel MWM, van Hattum AH, Snow GB, Leemans CR. Prognostic importance of paratracheal lymph node metastases. Laryngoscope 2005; 115 (5): 894-898.
    PM:15867661

66. IF (2004): 4.297
    Pos F, Horenblas S, Dom P, Moonen L, Bartelink H. Organ preservation in invasive bladder cancer: Brachytherapy, an alternative to cystectomy and combined modality treatment? Int J Radiat Oncol Biol Phys 2005; 61 (3): 678-686.
    PM:15708245 

67. IF (2004): 0.727
    Preti M, van Seters M, Sideri M, Van Beurden M. Squamous Vulvar Intraepithelial Neoplasia. Clin Obstet Gynecol 2005; 48 (4): 845-861.
    PM:16286831 

68. IF (2004): 5.623
    Rademaker-Lakhai JM, Horenblas S, Meinhardt W, Stokvis E, de Reijke TM, Jimeno JM, Lopez-Lazaro L, Lopez Martin JA, Beijnen JH, Schellens JHM. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin Cancer Res 2005; 11 (5): 1854-1862.
    PM:15756010 

69. IF (2004): geen
    Reinartz SM, Lohuis PJFM, Vermeersch HB, Smeele LE. Macroglossia: An indication for tonque reduction? [Macroglossie; een indicatie voor tongreductie?]. Ned Tijdschr KNO-Heelkd 2005; 11 (4): 195-199.

     

70. IF (2004): 1.882
    Rutgers EJT. Guidelines to assure quality in breast cancer surgery. Eur J Surg Oncol 2005; 31 (6): 568-576.
    PM:16023942 

71. IF (2004): geen
    Smeele LE. Een vrouw met acute enkelzijdige zwelling van het gelaat [ingezonden]. Ned Tijdschr Geneeskd 2005; 149 1713

     

72. IF (2004): 0.929
    Smit LHM, Korse CM, Bonfrer JMG. Comparison of four different assays for determination of serum S-100B. Int J Biol Markers 2005; 20 (1): 34-42.
    PM:15832771 

73. IF (2004): 1.758
    Smit LHM, Nieweg OE, Korse CM, Bonfrer JMG, Kroon BBR. Significance of serum S-100B in melanoma patients before and after sentinel node biopsy. J Surg Oncol 2005; 90 (2): 66-69.
    PM:15844182 

74. IF (2004): 3.302
    Smit LHM, Korse CM, Hart AAM, Bonfrer JMG, Haanen JBAG, Kerst JM, Nieweg OE, de Gast GC. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 2005; 41 (3): 386-392.
    PM:15691637 

75. Smit,L.H.M. Clinical relevance of serum S-100B for melanoma patients [Klinische relevantie van serum S-100B bij melanoompati‰nten] [dissertation]. Utrecht University; 2005;

     

76. IF (2004): geen
    Smit LHM, Nieweg OE, de Gast GC, Vald‚s Olmos RA, Comans EFI, Kroon BBR. Metastasectomie bij stadium IV melanoom, te overwegen bij zorgvuldig geselecteerde pati‰nten. Ned Tijdschr Oncol 2005; 2 147-152.

     

77. IF (2004): 2.651
    Spermon JR, Hoffmann AL, Horenblas S, Verbeek AL, Witjes JA, Kiemeney LA. The efficacy of different follow-up strategies in clinical stage I Non-seminomatous Germ Cell Cancer: a Markov simulation study. Eur Urol 2005; 48 (2): 258-267.
    PM:15964134 

78. IF (2004): 2.748
    Steggerda M, Schneider C, Van Herk M, Zijp L, Moonen L, van der Poel H. The applicability of simultaneous TRUS-CT imaging for the evaluation of prostate seed implants. Med Phys 2005; 32 (7): 2262-2270.
    PM:16121581 

79. IF (2004): 3.439
    Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi, Fachiroh J, Paramita DK, Tan IB, Haryana SM, Middeldorp JM. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol 2005; 43 (7): 3066-3073.
    PM:16002393 

80. IF (2004): 1.758
    Takkenberg RB, Vrouenraets BC, van Geel AN, Nieweg OE, Noorda EM, Eggermont AM, Kroon BBR. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. J Surg Oncol 2005; 91 (2): 107-111.
    PM:16028280 

81. IF (2004): geen
    Tan ML, Lohuis PJFM, Balm AJM, Besnard APE. Mediastinal abscess following laryngoscopy after chemoirradiation for hypopharyngeal carcinoma [Mediastinaal abces als gevolg van laryngoscopie na chemo-irradiatie voor hypopharynxcarcinoom]. Ned Tijdschr KNO-Heelkd 2005; 11 (3): 139-141.

     

82. IF (2004): 1.758
    Tanis PJ, Van Rijk MC, Nieweg OE. The posterior lymphatic network of the breast rediscovered. J Surg Oncol 2005; 91 (3): 195-198.
    PM:16118774 

83. IF (2004): 0.686
    Van As-Brooks CJ, Hilgers FJM, Koopmans-van Beinum FJ, Pols LCW. Anatomical and functional correlates of voice quality in tracheoesophageal speech. J Voice 2005; 19 (3): 360-372.
    PM:15936923 

84. IF (2004): geen
    Van den Bongard HJGD, Van Beurden M, Zoetmulder FA, Peterse JL, Dewit L. Een patiënt met perianale morbus Bowen: een diagnostisch en therapeutisch dilemma. Ned Tijdschr Oncol 2005; 2 188-192.

     

85. IF (2004): geen
    van den Brekel MWM, Castelijns JA. What the clinician wants to know: surgical perspective and ultrasound for lymph node imaging of the neck. Cancer Imaging 2005; 5 Suppl S41-S49
    PM:16361135 

86. IF (2004): 2.651
    Van der Poel HG, Antonini N, Van Tinteren H, Horenblas S. Upper urinary tract cancer: location is correlated with prognosis. Eur Urol 2005; 48 (3): 438-444.
    PM:16115524 

87. IF (2004): 2.651
    Van der Poel HG. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer. Eur Urol 2005; 48 1051-1058.
    PM:16257107 

88. IF (2004): geen
    Van der Poel HG, Horenblas S, Teertstra HJ. Unexpected histology after nephrectomy for renal tumors [Onverwachte histopathologie bij nefrectomie]. Ned Tijdschr Urol 2005; 13 (5): 121-129.

     

89. IF (2004): 4.035
    van Duijnhoven FH, Rovers JP, Engelmann K, Krajina Z, Purkiss SF, Zoetmulder FAN, Vogl TJ, Terpstra OT. Photodynamic Therapy With 5,10,15,20-Tetrakis(m-Hydroxyphenyl) Bacteriochlorin for Colorectal Liver Metastases Is Safe and Feasible: Results From a Phase I Study. Ann Surg Oncol 2005; 12 808-816.
    PM:16132377 

90. IF (2004): geen
    van Everdingen JJE, van der Rhee HJ, Koning CEE, Nieweg OE, Kruit WHJ, Coebergh JWW, Ruiter DJ. Richtlijn "Melanoom"(3e herziening). Ned Tijdschr Geneeskd 2005; 149 (33): 1839-1843.

     

91. IF (2004): 5.623
    van Poelgeest MI, van Seters M, Van Beurden M, Kwappenberg KM, Heijmans-Antonissen C, Drijfhout JW, Melief CJ, Kenter GG, Helmerhorst TJ, Offringa R, van der Burg SH. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 2005; 11 (14): 5273-5280.
    PM:16033846 

92. IF (2004): 2.651
    van Rhijn BW, Van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review 362. Eur Urol 2005; 47 (6): 736-748.
    PM:15925067 

93. IF (2004): geen
    Van Rhijn BWG, Van der Poel HG, van der Kwast T. Urine markers for bladder cancer surveillance: A systematic review [Urinemarkers voor blaaskanker-follow-up: Een systematische review]. Ned Tijdschr KNO-Heelkd 2005; 13 (7): 189-196.

     

94. IF (2004): 1.758
    Van Rijk MC, Nieweg OE, Vald‚s Olmos RA, Rutgers EJT, Hoefnagel CA, Kroon BBR. Non-axillary breast cancer recurrences after sentinel node biopsy. J Surg Oncol 2005; 92 (4): 292-298.
    PM:16299804 

95. IF (2004): 2.083
    van Seters M, Van Beurden M, de Craen AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients 364. Gynecol Oncol 2005; 97 (2): 645-651.
    PM:15863172 

96. IF (2004): 3.742
    van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, Van Asperen CJ, Rutgers EJT, Van't Veer LJ, Tollenaar RA. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005; 93 (3): 287-292.
    PM:16052221 

97. IF (2004): geen
    Van Zandwijk N, Burgers S, Klomp HM, De Jaeger K, Visser C, Veldhuijzen J. Sneller en beter: alle diagnostiek op ‚‚n dag geeft kwaliteitsimpuls. Med Contact 2005; 39 1362-1363.

     

98. IF (2004): 3.302
    Vasen HF, Tesfay E, Boonstra H, Mourits MJ, Rutgers E, Verheyen R, Oosterwijk J, Beex L. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer 2005; 41 (4): 549-554.
    PM:15737559 

99. IF (2004): 2.651
    Verra N, De Jong D, Bex A, Batchelor D, Dellemijn T, Sein J, Nooijen W, Meinhardt W, Horenblas S, de Gast G, Vyth-Dreese F. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol 2005; 48 (3): 527-533.
    PM:16115526 

100. IF (2004): 4.035
     Verwaal VJ, Van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FAN. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12 (1): 65-71.
     PM:15827780 

101. IF (2004): 3.713
     Visser O, Nieuwenhuijzen JA, Horenblas S. Local recurrence after cystectomy and survival of patients with bladder cancer: a population based study in greater amsterdam. J Urol 2005; 174 (1): 97-102.
     PM:15947586 

102. IF (2004): 3.302
     Voogd AC, van Oost FJ, Rutgers EJT, Elkhuizen PH, van Geel AN, Scheijmans LJ, van der Sangen MJ, Botke G, Hoekstra CJ, Jobsen JJ, van de Velde CJ, von Meyenfeldt MF, Tabak JM, Peterse JL, Van de Vijver MJ, Coebergh JW, van Tienhoven G. Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer 2005; 41 2637-2641.
     PM:16115758 

103. IF (2004): geen
     Vos E, Verwaal V, van Harten W. De lijdensweg van een medische innovatie: pati‰nten gedupeerd door bureaucratisch getreuzel. Med Contact 2005; 60 1807-1809.

      

104. IF (2004): 0.900
     Woerdeman LAE, Hage JJ, van Turnhout AAWM. Extended deepithelialization to secure double-breasted closure of the skin. Ann Plast Surg 2005; 55 (3): 338-340.
     PM:16106180 

105. Woerdeman,L.A.E. Surgical risk factors of breast reconstruction and their clinical implications [dissertation]. University of Amsterdam; 2005;

      

106. Zoetmulder F. Opereren op weg naar genezing: Alles over chirurgie bij kanker. Wormer: Inmerc BV; 2005;

      

107. IF (2004): 9.023
     Zoetmulder FAN, Smeenk RM, Verwaal VJ. Curative treatment of peritoneal carcinomatosis of colorectal origin. EJC Suppl 2005; 3 (3): 411-413.

se-XII=PSOE   (42)

1. Aaronson NK. Lipscomb J, Gotay CC, Snyder C, editors.Outcomes assessment in cancer: measures, methods, and applications. Cambridge: Cambridge University Press, 2005; 20, Cross-cultural use of health-related quality of life assessments in clinical oncology. p. 406-24.

    

2. IF (2004): 3.038
   Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA, Easton DF. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 2005; 29 (1): 1-11.
   PM:15880399 

3. IF (2004): geen
   Bleiker E, Wigbout G, van Rens A, Verhoef S, van't Veer L, Aaronson N. Withdrawal from genetic counselling for cancer. Hereditary Cancer Clin Pract 2005; 3 19-27.

    

4. IF (2004): 13.092
   Bleiker EM, Menko FH, Taal BG, Kluijt I, Wever LD, Gerritsma MA, Vasen HFA, Aaronson NK. Screening behavior of individuals at high risk for colorectal cancer. Gastroenterology 2005; 128 (2): 280-287.
   PM:15685539 

5. IF (2004): 3.302
   Bredart A, Bottomley A, Blazeby JM, Conroy T, Coens C, D'Haese S, Chie WC, Hammerlid E, Arraras JI, Efficace F, Rodary C, Schraub S, Costantini M, Costantini A, Joly F, Sezer O, Razavi D, Mehlitz M, Bielska-Lasota M, Aaronson NK. An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32). Eur J Cancer 2005; 41 (14): 2120-2131.
   PM:16182120 

6. Coebergh JWW, Van Leeuwen FE, Vandenbroucke JP. Van de Velde CJH, Van Krieken JHJM, De Mulder PHM, Vermorken JB, editors.Oncologie; zevende, herziene druk. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2005; 2, Oorzaken en frequentie van kanker. p. 27-51.

    

7. Coebergh JWW, Vandenbroucke JP, Van Leeuwen FE. Van de Velde CJH, Van Krieken JHJM, De Mulder PHM, Vermorken JB, editors.Oncologie; zevende, herziene druk. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2005; 3, Prognose en screening van kanker. p. 53-71.

    

8. IF (2004): 9.835
   Coens C, Bottomley A, Efficace F, Flechtner H, Aaronson N. Variability and sample size requirements for health-related quality-of-life measures: understanding the challenges facing investigators [letter]. J Clin Oncol 2005; 23 (33): 8541-8542.
   PM:16293886 

9. IF (2004): 2.992
   De Boer EJ, Den Tonkelaar I, Burger CW, Van Leeuwen FE. Are cause of subfertility and in vitro fertilization treatment risk factors for an earlier start of menopause? Menopause 2005; 12 (5): 578-588.
   PM:16145312 

10. IF (2004): 4.933
    De Boer EJ, Den Tonkelaar I, Burger CW, Van Leeuwen FE, on behalf of the OMEGA Project Group. Validity of self-reported causes of subfertility. Am J Epidemiol 2005; 161 (10): 978-986.
    PM:15870163 

11. IF (2004): 9.782
    Hill DA, Gilbert E, Dores GM, Gospodarowicz M, Van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer M, Storm H, Pukkala E, Stovall M, Curtis RE, Allan JM, Boice JD, Travis LB. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood 2005; 106 3358-3365.
    PM:16051739 

12. IF (2004): geen
    Hoogendoorn WE, Casparie MK, Van Leeuwen FE. [Rapid tracing of new patients with cancer through the nationwide network and registry of histo- and cytopathology in the netherlands (PALGA) in order to freeze tumour material for molecular-epidemiological research] Snelle signalering van nieuwe patienten met kanker via het Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief (PALGA) zodat tumormateriaal kan worden ingevroren voor moleculair-epidemiologisch onderzoek. Ned Tijdschr Geneeskd 2005; 149 (40): 2222-2227.
    PM:16235800 

13. IF (2004): 3.302
    In der Maur CD, Klokman WJ, Van Leeuwen FE, Tan IB, Rutgers EJT, Balm AJM. Increased risk of breast cancer development after diagnosis of salivary gland tumour. Eur J Cancer 2005; 41 (9): 1311-1315.
    PM:15939266 

14. IF (2004): 9.835
    Knols R, Aaronson NK, Uebelhart D, Fransen J, Aufdemkampe G. Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol 2005; 23 (16): 3830-3842.
    PM:15923576 

15. IF (2004): 3.310
    Kreukels BPC, Schagen SB, Ridderinkhof KR, Boogerd W, Hamburger HL, Van Dam FSAM. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 2005; 94 (1): 53-61.
    PM:16175317 

16. Langendijk H, Aaronson NK. Jeremic B, editors.Advances in radiation oncology in lung cancer. Springer, 2005;Quality of life in radiation oncology of lung cancer. p. 395-410.

     

17. IF (2004): 3.365
    Lintsen AM, Pasker-de Jong PC, De Boer EJ, Burger CW, Jansen CA, Braat DD, Van Leeuwen FE. Effects of subfertility cause, smoking and body weight on the success rate of IVF. Hum Reprod 2005; 20 (7): 1867-1875.
    PM:15817580 

18. IF (2004): 9.835
    Madalinska JB, Hollenstein J, Bleiker E, Van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. Quality-of-Life Effects of Prophylactic Salpingo-Oophorectomy Versus Gynecologic Screening Among Women at Increased Risk of Hereditary Ovarian Cancer. J Clin Oncol 2005; 23 6890-6898.
    PM:16129845 

19. IF (2004): 2.654
    Petersen MA, Groenvold M, Aaronson N, Brenne E, Fayers P, Nielsen JD, Sprangers M, Bjorner JB. Scoring based on item response theory did not alter the measurement ability of EORTC QLQ-C30 scales. J Clin Epidemiol 2005; 58 (9): 902-908.
    PM:16085193 

20. IF (2004): 3.302
    Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lanteri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005; 41 (8): 1135-1139.
    PM:15911236 

21. Signaleringscommissie Kanker van KWF Kankerbestrijding, Van Leeuwen FE. De rol van lichaamsbeweging bij de preventie van kanker
    90. Amsterdam: KWF Kankerbestrijding; 2005;

     

22. IF (2004): 3.310
    Soerjomataram I, Louwman WJ, de Vries E, Lemmens VE, Klokman WJ, Coebergh JW. Primary malignancy after primary female breast cancer in the South of the Netherlands, 1972-2001. Breast Cancer Res Treat 2005; 93 (1): 91-95.
    PM:16184464 

23. IF (2004): 3.302
    Soerjomataram I, Louwman WJ, Lemmens VEPP, de Vries E, Klokman WJ, Coebergh JWW. Risks of second primary breast and urogenital cancer following female breast cancer in the south of The Netherlands, 1972-2001. Eur J Cancer 2005; 41 (15): 2331-2337.
    PM:16140007 

24. Sprangers MAG, Aaronson NK, de Haes JCJM. Van de Velde CJH, Van Krieken JHJM, De Mulder PHM, Vermorken JB, editors.Oncologie; zevende, herziene druk. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2005; 37, Onderzoek naar de kwaliteit van leven van kankerpati‰nten. p. 513-8.

     

25. IF (2004): 4.297
    Stalpers LJA, da Costa HC, Merbis MAE, Fortuin AA, Muller MJ, Van Dam FSAM. Hypnotherapy in radiotherapy patients: A randomized trial. Int J Radiat Oncol Biol Phys 2005; 61 (2): 499-506.
    PM:15667973 

26. Swerdlow AJ, Van Leeuwen FE. Degos L, Linch DC, L”wenberg B, editors.Textbook of malignant hematology; second edition. London: Taylor & Francis, 2005;Late effects after treatment for Hodgkin lymphoma. p. 753-68.

     

27. IF (2004): 13.856
    Travis LB, Hill D, Dores GM, Gospodarowicz M, Van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF, Pee D, Smith SA, Van't Veer MB, Joensuu T, Storm H, Stovall M, Boice JD, Jr., Gilbert E, Gail MH. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97 (19): 1428-1437.
    PM:16204692 

28. IF (2004): 4.112
    Van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HFA, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Hogervorst FB, van Houwelingen JC, Van't Veer LJ, Rookus MA, Van Leeuwen FE. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005; 42 (9): 711-719.
    PM:16141007 

29. Van Dam FSAM. Van de Velde CJH, Van Krieken JHJM, De Mulder PHM, Vermorken JB, editors.Oncologie; zevende, herziene druk. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2005; 36, Psychosociale zorg voor de kankerpati‰nt. p. 505-11.

     

30. Van Dam FSAM. van Maanen H, editors.Kwakzalverij: 125 jaar medische folklore. Amsterdam: Boom, 2005;Het echec van alternatieve kankerbehandelingen. p. 103-7.

     

31. IF (2004): 4.061
    van den Heuvel SG, van der Beek AJ, Blatter BM, Hoogendoorn WE, Bongers PM. Psychosocial work characteristics in relation to neck and upper limb symptoms. Pain 2005; 114 (1-2): 47-53.
    PM:15733630 

32. IF (2004): 3.515
    van der Pal HJ, van Dalen EC, Kremer LC, Bakker PJ, Van Leeuwen FE. Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review. Cancer Treat Rev 2005; 31 (3): 173-185.
    PM:15896910 

33. Van der Zouwe N, Van Dam FSAM. Van de Velde CJH, Van Krieken JHJM, De Mulder PHM, Vermorken JB, editors.Oncologie; zevende, herziene druk. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2005; 42, Het gebruik van alternatieve kankertherapie‰n naast de reguliere behandeling. p. 563-70.

     

34. Van Leeuwen FE. Signaleringscommissie Kanker van KWF Kankerbestrijding, editors.De rol van lichaamsbeweging bij preventie van kanker. Amsterdam: KWF Kankerbestrijding, 2005;Voorwoord. p. 9-10.

     

35. Van Leeuwen FE, Travis LB. DeVita Jr VT, Hellman S, Rosenberg SA, editors.Cancer: principles and practice of oncology, 7th ed. Philadelphia: Lippincot Williams & Wilkins, 2005;Second cancers. p. 2575-602.

     

36. Van Luijn H, Aaronson N, Keus R, et al. Risks and benefits of experimental treatments in oncology: Research into the decision-making of institutional review boards. Amsterdam: Blaise Pascal Instituut, Vrije Universiteit; 2005;

     

37. IF (2004): 3.742
    van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, Van Asperen CJ, Rutgers EJT, Van't Veer LJ, Tollenaar RA. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005; 93 (3): 287-292.
    PM:16052221 

38. IF (2004): 3.302
    Visser O, Van Leeuwen FE. Stage-specific survival of epithelial cancers in North-Holland/Flevoland, The Netherlands. Eur J Cancer 2005; 41 2321-2330.
    PM:16125930 

39. IF (2004): 1.785
    Visser O, van Peppen AM, Ory FG, Van Leeuwen FE. Results of breast cancer screening in first generation migrants in Northwest Netherlands. Eur J Cancer Prev 2005; 14 (3): 251-255.
    PM:15901994 

40. IF (2004): 1.551
    Visser O, van Wijnen JH, Van Leeuwen FE. Incidence of cancer in the area around Amsterdam Airport Schiphol in 1988-2003: a population-based ecological study. BMC Public Health 2005; 5 (1): 127
    PM:16332253 

41. IF (2004): 4.500
    Voskuil DW, Vrieling A, Van't Veer LJ, Kampman E, Rookus MA. The insulin-like growth factor (IGF) system in cancer prevention: potential of dietary intervention strategies. Cancer Epidemiol Biomarkers Prev 2005; 13 195-203.
    PM:16041870 

42. IF (2004): 1.820
    Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 2005; 14 (2): 285-295.
    PM:15892420

se-XIII=diagn.oncol.   (77)

1. IF (2004): 2.216
   Bardelmeijer HA, Roelofs AB, Hillebrand MJ, Beijnen JH, Schellens JHM, Tellingen OV. Metabolism of docetaxel in mice. Cancer Chemother Pharmacol 2005; 56 299-306.
   PM:15864592

2. IF (2004): 14.588
   Bende RJ, Aarts WM, Riedl RG, De Jong D, Pals ST, van Noesel CJ. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005; 201 (8): 1229-1241.
   PM:15837810 

3. IF (2004): 2.585
   Bex A, Nieuwenhuijzen JA, Kerst M, Pos F, Van Boven H, Meinhardt W, Horenblas S. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology 2005; 65 (2): 295-299.
   PM:15708041 

4. IF (2004): geen
   Bleiker E, Wigbout G, van Rens A, Verhoef S, van't Veer L, Aaronson N. Withdrawal from genetic counselling for cancer. Hereditary Cancer Clin Pract 2005; 3 19-27.

    

5. IF (2004): 7.690
   Breedveld P, Pluim D, Cipriani G, Wielinga P, Van Tellingen O, Schinkel AH, Schellens JHM. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005; 65 (7): 2577-2582.
   PM:15805252 

6. IF (2004): 2.098
   Brouwers EE, Tibben MM, Joerger M, Van Tellingen O, Rosing H, Schellens JHM, Beijnen JH. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Anal Bioanal Chem 2005; 382 (7): 1484-1490.
   PM:15952001 

7. IF (2004): 10.452
   Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, Van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, Van de Vijver MJ. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005; 102 (10): 3738-3743.
   PM:15701700 

8. IF (2004): 7.690
   Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, Stoughton R, Friend S. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005; 65 (10): 4059-4066.
   PM:15899795 

9. IF (2004): 9.835
   De Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005; 23 (26): 6358-6363.
   PM:16155020 

10. De Jong D, Raemaekers J. Van de Velde CJH, Van Krieken JHJM, De Mulder PHM, Vermorken JB, editors.Oncologie; zevende, herziene druk. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2005; 31, Maligne aandoeningen van het lymfatische systeem. p. 461-74.

     

11. IF (2004): 9.624
    Dekker LJ, Boogerd W, Stockhammer G, Dalebout JC, Siccama I, Zheng P, Bonfrer JM, Verschuuren JJ, Jenster G, Verbeek MM, Luider TM, Smitt PA. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol Cell Proteomics 2005; 4 (9): 1341-1349.
    PM:15970584 

12. IF (2004): 4.690
    Del Vecchio M, Foschini MP, Peterse JL, Eusebi V. Lobular Carcinoma of the Breast With Hybrid Myoepithelial and Secretory ("Myosecretory") Cell Differentiation. Am J Surg Pathol 2005; 29 (11): 1530-1536.
    PM:16224222 

13. IF (2004): 5.076
    Deurloo EE, Muller SH, Peterse JL, Besnard AP, Gilhuijs KGA. Clinically and mammographically occult breast lesions on MR images: potential effect of computerized assessment on clinical reading. Radiology 2005; 234 (3): 693-701.
    PM:15650040 

14. IF (2004): 3.302
    Deurloo EE, Peterse JL, Rutgers EJT, Besnard APE, Muller SH, Gilhuijs KGA. Additional breast lesions in patients eligible for breast-conserving therapy by MRI: impact on preoperative management and potential benefit of computerised analysis 176. Eur J Cancer 2005; 41 (10): 1393-1401.
    PM:15913987 

15. Deurloo,E.E. Correlation of diagnostic breast imaging data and pathology: application to diagnosis and treatment [dissertation]. University of Amsterdam; 2005;

     

16. IF (2004): 1.147
    Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005; 15 (5): 679-691.
    PM:16174214 

17. IF (2004): 2.549
    El Zimaity HM, Wotherspoon A, De Jong D. Interobserver variation in the histopathological assessment of malt/malt lymphoma: towards a consensus 185. Blood Cells Mol Dis 2005; 34 (1): 6-16.
    PM:15607694 

18. Faneyte,I.F. Markers for effectiveness of chemotherapy and drug resistance in breast cancer [dissertation]. University of Amsterdam; 2005;

     

19. IF (2004): 9.782
    Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, Chiorazzi M, Iqbal J, Gesk S, Siebert R, De Jong D, Jaffe ES, Wilson WH, Delabie J, Ott G, Dave BJ, Sanger WG, Smith LM, Rimsza L, Braziel RM, Muller-Hermelink HK, Campo E, Gascoyne RD, Staudt LM, Chan WC. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106 (13): 4315-4321.
    PM:16123218 

20. IF (2004): 5.623
    Geurts TW, Nederlof PM, van den Brekel MWM, Van't Veer LJ, De Jong D, Hart AAM, Van Zandwijk N, Klomp H, Balm AJM, van Velthuysen MLF. Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clin Cancer Res 2005; 11 (18): 6608-6614.
    PM:16166439 

21. IF (2004): 9.782
    Glas AM, Kersten MJ, Delahaye LJ, Witteveen AT, Kibbelaar RE, Velds A, Wessels LFA, Joosten P, Kerkhoven RM, Bernards R, Van Krieken JHJM, Kluin PM, Van't Veer LJ, De Jong D. Gene expression profiling in follicular l ymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105 301-307.
    PM:15345589 

22. IF (2004): 3.302
    Haas RL, Poortmans P, De Jong D, Verheij M, van der Hulst M, de Boer JP, Bartelink H. Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. Eur J Cancer 2005; 41 (12): 1724-1730.
    PM:16039113 

23. IF (2004): 9.835
    Hannemann J, Oosterkamp HM, Bosch CAJ, Velds A, Wessels LFA, Loo C, Rutgers EJ, Rodenhuis S, Van de Vijver MJ. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005; 23 (15): 3331-3342.
    PM:15908647 

24. IF (2004): 1.464
    Horlings H, Demant P. Lung tumor location and lymphocyte infiltration in mice are genetically determined. Exp Lung Res 2005; 31 (5): 513-525.
    PM:16019985 

25. IF (2004): 3.520
    Kerst JM, Bex A, Mallo H, Dewit L, Haanen JB, Boogerd W, Teertstra HJ, de Gast GC. Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. Cancer Immunol Immunother 2005; 54 (9): 926-931.
    PM:15906025 

26. IF (2004): 5.333
    Kluiver J, Poppema S, De Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 2005; 207 (2): 243-249.
    PM:16041695  

27. IF (2004): 2.000
    Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linhorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, De Koning HJ, Rutgers T, Klijn JG. Efficacy of Magnetic Resonance Imaging and Mammography for Breast Cancer Screening in Women With a Familial or Genetic Predisposition. Obstet Gynecol Surv 2005; 60 (2): 107-109.
    PM:15671899 

28. IF (2004): 1.582
    Kroon BK, Vald‚s Olmos RA, Van der Poel HG, Nieweg OE, Horenblas S. Prepubic sentinel node location in penile carcinoma. Clin Nucl Med 2005; 30 (10): 649-650.
    PM:16166835

29. IF (2004): 2.089
    Kroon BK, Horenblas S, Deurloo EE, Nieweg OE, Teertstra HJ. Ultrasonography-guided fine-needle aspiration cytology before sentinel node biopsy in patients with penile carcinoma. BJU Int 2005; 95 (4): 517-521.
    PM:15705071 

30. IF (2004): 3.713
    Kroon BK, Lont AP, Vald‚s Olmos RA, Nieweg OE, Horenblas S. Morbidity of dynamic sentinel node biopsy in penile carcinoma. J Urol 2005; 173 (3): 813-815.
    PM:15711275 

31. IF (2004): 3.713
    Kroon BK, Vald‚s Olmos RA, Van Tinteren H, Nieweg OE, Horenblas S. Reproducibility of lymphoscintigraphy for lymphatic mapping in patients with penile carcinoma. J Urol 2005; 174 (6): 2214-2217.
    PM:16280766 

32. IF (2004): 3.935
    Kroon BK, Vald‚s Olmos RA, Nieweg OE, Horenblas S. Non-visualization of sentinel lymph nodes in penile carcinoma. Eur J Nucl Med Mol Imaging 2005; 32 (9): 1096-1099.
    PM:15875177 

33. IF (2004): 2.651
    Kroon BK, Horenblas S, Meinhardt W, Van der Poel HG, Bex A, Van Tinteren H, Valdes Olmos RA, Nieweg OE. Dynamic sentinel node biopsy in penile carcinoma: evaluation of 10 years experience. Eur Urol 2005; 47 (5): 601-606.
    PM:15826750 

34. IF (2004): 5.623
    Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11 (14): 5175-5180.
    PM:16033833 

35. IF (2004): 3.310
    Lippman ME, Benz C, Chinnaiyan A, Flockhart D, Harris A, Hudis C, Osborne CK, Press MF, Rae J, Sledge GW, van't Veer L, Wicha M. Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'. Breast Cancer Res Treat 2005; 90 (1): 1-3.
    PM:15770520 

36. IF (2004): 9.835
    Luiten RM, Kueter EW, Mooi W, Gallee MPW, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC. Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients. J Clin Oncol 2005; 23 8978-8991.
    PM:16260696 

37. IF (2004): 1.408
    Luppino FS, Pameijer FA, Balm AJM. Radiology quiz case 2. Laryngeal plasmacytoma in a patient with known multiple myeloma (MM). Arch Otolaryngol Head Neck Surg 2005; 131 (1): 74
    PM:15655194 

38. IF (2004): geen
    Meij V, Zuetenhorst JM, Van Hillegersberg R, Kroger R, Prevoo W, Van Coevorden F, Taal BG. Local treatment in unresectable hepatic metastases of carcinoid tumors: Experiences with hepatic artery embolization and radiofrequency ablation. World J Surg Oncol 2005; 3 (1): 75
    PM:16293186 

39. IF (2004): 1.882
    Meijnen P, Peterse JL, Oldenburg HSA, Woerdeman LAE, Rutgers EJT. Changing patterns in diagnosis and treatment of ductal carcinoma in situ of the breast. Eur J Surg Oncol 2005; 31 (8): 833-839.
    PM:15923104 

40. IF (2004): 4.112
    Nielsen M, Franken PF, Reinards TH, Weiss MM, Wagner A, van der Klift H, Kloosterman S, Houwing-Duistermaat JJ, Aalfs CM, Ausems MG, Brocker-Vriends AH, Gomez Garcia EB, Hoogerbrugge N, Menko FH, Sijmons RH, Verhoef S, Kuipers EJ, Morreau H, Breuning MH, Tops CM, Wijnen JT, Vasen HF, Fodde R, Hes FJ. Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP) 277. J Med Genet 2005; 42 (9): e54
    PM:16140997 

41. IF (2004): 3.935
    Nieweg OE, Van Rijk MC, Vald‚s Olmos RA, Hoefnagel CA. Sentinel node biopsy and selective lymph node clearance--impact on regional control and survival in breast cancer and melanoma 281. Eur J Nucl Med Mol Imaging 2005; 32 (6): 631-634.
    PM:15875179 

42. IF (2004): 3.805
    Oestreicher N, Ramsey SD, Linden HM, McCune JS, Van't Veer LJ, Burke W, Veenstra DL. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med 2005; 7 (6): 380-389.
    PM:16024969 

43. IF (2004): 2.083
    Olivier RI, Lubsen-Brandsma LA, Van Boven H, Van Beurden M. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense? Gynecol Oncol 2005; 96 (2): 439-443.
    PM:15661233 

44. IF (2004): 2.216
    Press RR, Buckle T, Beijnen JH, Van Tellingen O. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. Cancer Chemother Pharmacol 2005; 1-7.
    PM:16163538 

45. IF (2004): 9.835
    Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005; 23 (31): 7804-7810.
    PM:16219936 

46. IF (2004): 5.973
    Reijneveld JC, Brandsma D, Boogerd W, Bonfrer JGM, Kalmijn S, Voest EE, Geurts-Moespot A, Visser MC, Taphoorn MJ. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 2005; 65 (7): 1120-1122.
    PM:16217072 

47. IF (2004): 24.695
    Roepman P, Wessels LFA, Kettelarij N, Kemmeren P, Miles AJ, Lijnzaad P, Tilanus MG, Koole R, Hordijk GJ, van der Vliet PC, Reinders MJ, Slootweg PJ, Holstege FCP. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 2005; 37 (2): 182-186.
    PM:15640797 

48. IF (2004): 2.741
    Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, van den Ouweland A. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet 2005; 13 (6): 731-741.
    PM:15798777 

49. IF (2004): 5.333
    Schraders M, De Jong D, Kluin P, Groenen P, van Krieken H. Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation. J Pathol 2005; 205 (3): 329-335.
    PM:15682435 

50. IF (2004): 3.195
    Schreuder MI, Hoeve MA, Groothuis L, Boot H, Boerrigter LH, De Jong D, Veenendaal RA, Jansen JH, Van Krieken JHJM. Monitoring gastric lymphoma in peripheral blood by quantitative IgH allele-specific oligonucleotide real-time PCR and API2-MALT1 PCR. Br J Haematol 2005; 131 (5): 619-623.
    PM:16351637 

51. IF (2004): 0.929
    Smit LHM, Korse CM, Bonfrer JMG. Comparison of four different assays for determination of serum S-100B. Int J Biol Markers 2005; 20 (1): 34-42.
    PM:15832771 

52. IF (2004): 1.758
    Smit LHM, Nieweg OE, Korse CM, Bonfrer JMG, Kroon BBR. Significance of serum S-100B in melanoma patients before and after sentinel node biopsy. J Surg Oncol 2005; 90 (2): 66-69.
    PM:15844182 

53. IF (2004): 3.302
    Smit LHM, Korse CM, Hart AAM, Bonfrer JMG, Haanen JBAG, Kerst JM, Nieweg OE, de Gast GC. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 2005; 41 (3): 386-392.
    PM:15691637 

54. IF (2004): geen
    Smit LHM, Nieweg OE, de Gast GC, Vald‚s Olmos RA, Comans EFI, Kroon BBR. Metastasectomie bij stadium IV melanoom, te overwegen bij zorgvuldig geselecteerde pati‰nten. Ned Tijdschr Oncol 2005; 2 147-152.

     

55. IF (2004): geen
    Tan ML, Lohuis PJFM, Balm AJM, Besnard APE. Mediastinal abscess following laryngoscopy after chemoirradiation for hypopharyngeal carcinoma [Mediastinaal abces als gevolg van laryngoscopie na chemo-irradiatie voor hypopharynxcarcinoom]. Ned Tijdschr KNO-Heelkd 2005; 11 (3): 139-141.

     

56. IF (2004): 3.302
    Tilanus-Linthorst MMA, Kriege M, Boetes C, Hop WCJ, Obdeijn IM, Oosterwijk JC, Peterse HL, Zonderland HM, Meijer S, Eggermont AMM, De Koning HJ, Klijn JGM, Brekelmans CTM. Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer 2005; 41 (11): 1610-1617.
    PM:15978801 

57. IF (2004): 9.835
    van't Veer L, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 2005; 23 (8): 1631-1635.
    PM:15755970 

58. IF (2004): geen
    Van't Veer LJ, Rodenhuis S, Van de Vijver MJ. Prognostische betekenis van het genexpressieprofiel van mammatumoren, bepaald met DNA-microarrays. Ned Tijdschr Geneeskd 2005; 149 638-646.

     

59. IF (2004): 4.112
    Van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HFA, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Hogervorst FB, van Houwelingen JC, Van't Veer LJ, Rookus MA, Van Leeuwen FE. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005; 42 (9): 711-719.
    PM:16141007 

60. IF (2004): 7.690
    Van Beers EH, Van Welsem T, Wessels LFA, Oldenburg RA, Devilee P, Cornelisse CJ, Verhoef S, Hogervorst FBL, Van't Veer LJ, Nederlof PM. CGH profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 2005; 65 822-827.

     

61. IF (2004): 4.623
    van de Vijver M. Gene-expression profiling and the future of adjuvant therapy. Oncologist 2005; 10 Suppl 2 30-34.
    PM:16272457 

62. IF (2004): 9.023
    van de Vijver M. Current and future pathological examination in breast cancer. EJC Suppl 2005; 3 (3): 121-130.

     

63. IF (2004): 0.760
    Van de Vijver MJ. Biological variables and prognosis of DCIS. Breast 2005; 14 509-519.
    PM:16246564 

64. IF (2004): geen
    Van den Bongard HJGD, Van Beurden M, Zoetmulder FA, Peterse JL, Dewit L. Een pati‰nt met perianale morbus Bowen: een diagnostisch en therapeutisch dilemma. Ned Tijdschr Oncol 2005; 2 188-192.

     

65. IF (2004): 1.758
    Van Rijk MC, Nieweg OE, Vald‚s Olmos RA, Rutgers EJT, Hoefnagel CA, Kroon BBR. Non-axillary breast cancer recurrences after sentinel node biopsy. J Surg Oncol 2005; 92 (4): 292-298.
    PM:16299804 

66. IF (2004): 3.742
    van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, Van Asperen CJ, Rutgers EJT, Van't Veer LJ, Tollenaar RA. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005; 93 (3): 287-292.
    PM:16052221 

67. IF (2004): 1.667
    Van Tellingen O, Bardelmeijer HA, Buckle T, Ouwehand M, Beijnen JH, Schellens JHM. Cannulation of the jugular vein in mice 366. Lab Anim 2005; 39 (1): 130
    PM:15703135 

68. IF (2004): 2.955
    van Velthuysen MLF, Taal BG, van der Hoeven JJ, Peterse JL. Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma. Histopathology 2005; 46 (2): 153-157.
    PM:15693887 

69. IF (2004): 2.651
    Verra N, De Jong D, Bex A, Batchelor D, Dellemijn T, Sein J, Nooijen W, Meinhardt W, Horenblas S, de Gast G, Vyth-Dreese F. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol 2005; 48 (3): 527-533.
    PM:16115526 

70. IF (2004): 3.302
    Voogd AC, van Oost FJ, Rutgers EJT, Elkhuizen PH, van Geel AN, Scheijmans LJ, van der Sangen MJ, Botke G, Hoekstra CJ, Jobsen JJ, van de Velde CJ, von Meyenfeldt MF, Tabak JM, Peterse JL, Van de Vijver MJ, Coebergh JW, van Tienhoven G. Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer 2005; 41 2637-2641.
    PM:16115758 

71. IF (2004): 4.500
    Voskuil DW, Vrieling A, Van't Veer LJ, Kampman E, Rookus MA. The insulin-like growth factor (IGF) system in cancer prevention: potential of dietary intervention strategies. Cancer Epidemiol Biomarkers Prev 2005; 13 195-203.
    PM:16041870 

72. IF (2004): 3.742
    Weigelt B, Wessels LFA, Bosma AJ, Glas AM, Nuyten DS, He YD, Dai H, Peterse JL, Van't Veer LJ. No common denominator for breast cancer lymph node metastasis. Br J Cancer 2005; 93 (8): 924-932.
    PM:16189523 

73. IF (2004): 36.557
    Weigelt B, Peterse JL, Van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5 (8): 591-602.
    PM:16056258 

74. IF (2004): 7.690
    Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, Van't Veer LJ. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005; 65 (20): 9155-9158.
    PM:16230372 

75. IF (2004): 5.742
    Wessels LFA, Reinders MJT, Hart AAM, Veenman CJ, Dai H, He YD, Van't Veer LJ. A protocol for building and evaluating predictors of disease state based on microarray data. Bioinformatics 2005; 21 (19): 3755-3762.
    PM:15817694 

76. IF (2004): 13.868
    West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, Rubin BP, Montgomery K, Zhu S, Patel R, Hernandez-Boussard T, Goldblum JR, Brown PO, van de Vijver M, van de Rijn M. Determination of stromal signatures in breast carcinoma. PLoS Biol 2005; 3 (6): e187
    PM:15869330

77. IF (2004): 9.835
    Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, De Jong D, ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 2005; 23 (24): 5635-5643.
    PM:16110022 

     

se-BM=biometrics    (15)

1. IF (2004): 2.914
   Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, Van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005; 48 291-296.
   PM:15829331 

2. IF (2004): 1.104
   Bex A, Kerst J, Mallo H, Van Tinteren H, Horenblas S, de Gast GC. Extended continuous oral temozolomide in patients with progressive metastatic renal cell carcinoma not responding to interferon alpha 2b. J Chemother 2005; 17 (6): 674-678.
   PM:16433200 

3. IF (2004): 13.092
   Bleiker EM, Menko FH, Taal BG, Kluijt I, Wever LD, Gerritsma MA, Vasen HFA, Aaronson NK. Screening behavior of individuals at high risk for colorectal cancer. Gastroenterology 2005; 128 (2): 280-287.
   PM:15685539

4. IF (2004): 1.576
   den Herder C, Van Tinteren H, de Vries N. Hyoidthyroidpexia: a surgical treatment for sleep apnea syndrome. Laryngoscope 2005; 115 (4): 740-745.
   PM:15805891 

5. IF (2004): 1.576
   den Herder C, Van Tinteren H, de Vries N. Sleep endoscopy Versus Modified Mallampati Score in Sleep Apnea and Snoring. Laryngoscope 2005; 115 (4): 735-739.
   PM:15805890 

6. IF (2004): geen NKI; 3.118
   Herder GJ, Van Tinteren H, Golding RP, Kostense PJ, Comans EF, Smit EF, Hoekstra OS. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest 2005; 128 (4): 2490-2496.
   PM:16236914 

7. IF (2004): 9.835
   Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, Van Tinteren H, Postmus PE, Golding RP, Biesma B, Schramel FJ, Van Zandwijk N, Lammertsma AA, Hoekstra OS. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005; 23 (33): 8362-8370.
   PM:16293866 

8. IF (2004): 3.713
   Kroon BK, Vald‚s Olmos RA, Van Tinteren H, Nieweg OE, Horenblas S. Reproducibility of lymphoscintigraphy for lymphatic mapping in patients with penile carcinoma. J Urol 2005; 174 (6): 2214-2217.
   PM:16280766 

9. IF (2004): 2.651
   Kroon BK, Horenblas S, Meinhardt W, Van der Poel HG, Bex A, Van Tinteren H, Valdes Olmos RA, Nieweg OE. Dynamic sentinel node biopsy in penile carcinoma: evaluation of 10 years experience. Eur Urol 2005; 47 (5): 601-606.
   PM:15826750

10. IF (2004): 2.914
    Mathy A, Baas P, Dalesio O, Van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005; 50 (1): 83-86.
    PM:15951053 

11. IF (2004): 9.835
    Nieboer P, Buijs C, Rodenhuis S, Seynaeve C, Beex LV, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Mulder NH, van der Graaf WT, Tenvergert EM, Van Tinteren H, de Vries EG. Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study. J Clin Oncol 2005; 23 8296-8304.
    PM:16219926 

12. IF (2004): 3.713
    Nieuwenhuijzen JA, Horenblas S, Bex A, Kerst JM, Schornagel JH, Van Tinteren H, Meinhardt W. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol 2005; 174 80-85.
    PM:15947583 

13. IF (2004): 2.651
    Van der Poel HG, Antonini N, Van Tinteren H, Horenblas S. Upper urinary tract cancer: location is correlated with prognosis. Eur Urol 2005; 48 (3): 438-444.
    PM:16115524 

14. IF (2004): 9.835
    Van Tinteren H, Smit EF, Hoekstra OS. FDG-PET in addition to conventional work-up in non-small-cell lung cancer. J Clin Oncol 2005; 23 (7): 1591
    PM:15735147 

15. IF (2004): 2.619
    Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, Van Tinteren H, Harris AL, van Diest PJ, van der Wall E. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 2005; 58 (2): 172-177.
    PM:15677538

se-geen    (3)

1. IF (2004): 1.201
   Engbers LH, Vollenbroek-Hutten MM, van Harten WH. A comparison of patient characteristics and rehabilitation treatment content of chronic low back pain (CLBP) and stroke patients across six European countries. Health Policy 2005; 71 (3): 359-373.
   PM:15694502 

2. IF (2004): 5.333
   Oosterling SJ, van der Bij GJ, Meijer GA, Tuk CW, van Garderen E, van Rooijen N, Meijer S, van der Sijp JR, Beelen RH, van Egmond M. Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol 2005; 207 (2): 147-155.
   PM:16104052 

3. IF (2004): geen
   Vos E, Verwaal V, van Harten W. De lijdensweg van een medische innovatie: patiënten gedupeerd door bureaucratisch getreuzel. Med Contact 2005; 60 1807-1809.